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Introduction: Chronic kidney disease (CKD) is characterized by high 
cardiovascular (CV) risk and the RISCAVID study identified a correlation between 
CV risk and blood levels of sCD40L in uremia. Moreover, sCD40L correlates with 
osteoblastic differentiation of vascular smooth muscle cells (VSMC) and 
endothelial cells (EC) inflammation. In addition, CKD-related extracellular vesicles 
(EVs) express CD40L and polymethylmethacrylate (PMMA) dialyzer could reduce 
not only uremic toxins as indoxyl sulfate (IS), but also sCD40L and EVs by 
adsorption. 
Aim of the study: 1) identify a sCD40L predictive value for major cardiovascular 
events (MACE) in uremia, 2) assess the sCD40L role, 3) compare the efficacy of 
PMMA vs polysulfone (PS) in sCD40L and other molecule removal, and 4) perform 
CKD-EV characterization and analysis of their role CKD vascular damage. 
Patients and methods: In 201 dialysis patients from 6 Italian dialysis Centers, we 
assessed sCD40L and MACE during the follow-up. 48 high CV risk patients 
started 9 months randomized double-crossover study (treatment with PMMA or 
PS). We assessed SCD40L and biochemical parameters every 3 months. We 
evaluated sCD40L/IS mass removal and sCD40L effects on EC and VSMC in 
vitro. We characterized CKD-EVs and evaluate their role incubating EC and VSMC 
in vitro. 
Results: sCD40L cut-off of 7,8 ng/mL was the best predictor of MACE and PMMA 
was more efficient in reducing hepcidin, sCD40L and IS. PMMA decreased ROS 
production, monocyte adhesion and osteoblastic differentiation. CKD-EVs 
expressed CD40L and other inflammation markers, were internalized by EC and 
VSMC and modulated osteoblastic differentiation. 
Conclusions: sCD40L predicts MACE in CKD patients and PMMA is able to 
remove this molecule. sCD40L is not only a marker of CKD-CV damage, but also 
a mediator of progression. sCD40L and IS reduction could therefore have an 
impact on CKD-CV risk and CKD-EVs could also be considered true uremic toxins 
and effective mediators of damage. 
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Introduzione: La malattia renale cronica (CKD) è caratterizzata da un alto rischio 
cardiovascolare (CV) e lo studio RISCAVID ha identificato una correlazione tra il 
rischio CV e i livelli ematici di sCD40L nell'uremia. Inoltre, sCD40L correla con la 
differenziazione osteoblastica delle cellule muscolari lisce vascolari (VSMC) e 
delle cellule endoteliali (EC) infiammate. Le vescicole extracellulari (EV) 
plasmatiche nell’uremia esprimono CD40L e i filtri in polimetilmetacrilato (PMMA) 
potrebbero ridurre non solo le tossine uremiche come l’indoxil solfato (IS), ma 
anche sCD40L e EV tramite adsorbimento. 
Obiettivi: 1) identificare un valore predittivo sCD40L per eventi cardiovascolari 
maggiori (MACE) nell'uremia, 2) valutare il ruolo di sCD40L, 3) confrontare 
l'efficacia del PMMA vs polisulfone (PS) nella rimozione di sCD40L e altre 
molecole, e 4) eseguire una analisi delle CKD-EVs e del loro ruolo nella CKD. 
Pazienti e metodi: In 201 pazienti in dialisi da 6 Centri italiani, abbiamo valutato 
sCD40L e MACE nel follow-up. 48 pz ad alto rischio CV hanno iniziato uno studio 
randomizzato doppio-crossover di 9 mesi (trattamento con PMMA o PS). Abbiamo 
valutato SCD40L e parametri biochimici ogni 3 mesi, la rimozione di massa di 
sCD40L/IS e gli effetti di sCD40L su EC e VSMC in vitro. Abbiamo inoltre 
caratterizzato le CKD-EV valutandone il ruolo incubando EC e VSMC in vitro. 
Risultati: il cut-off di 7,8 ng/mL è risultato essere predittore di MACE. Il PMMA era 
più efficiente nel ridurre epcidina, sCD40L e IS e la produzione di ROS, adesione 
monocitaria e differenziazione osteoblastica in vitro. Le CKD-EV esprimono 
CD40L e altri marcatori di infiammazione, vengono internalizzate da EC e VSMC e 
modulano la differenziazione osteoblastica. 
Conclusioni: sCD40L predice MACE nei pazienti affetti da CKD e il PMMA è in 
grado di rimuovere efficacemente sCD40L e IS. sCD40L non è solo un indicatore 
di danno CV, ma anche di progressione. La riduzione di sCD40L e IS potrebbe 
avere un impatto sul rischio CV e le CKD-EV potrebbero anche essere 






2.1. Definition and staging of chronic kidney disease (CKD) 
CKD is defined by the presence of kidney damage or decreased kidney function 
for three or more months, irrespective of the cause1. The persistence of the 
damage or decreased function for at least three months is necessary to distinguish 
CKD from acute kidney disease. Kidney damage refers to pathologic 
abnormalities, whether established via kidney biopsy or imaging studies, or 
inferred from markers such as urinary sediment abnormalities or increased rates of 
urinary albumin excretion. Decreased kidney function refers to a decreased 
glomerular filtration rate (GFR), which is usually estimated (eGFR) using serum 
creatinine and one of several available equations. Based on GFR threshold, cause 
of disease and categories of albuminuria, CKD is classified and staged to guide 
management, including stratification of risk for progression and complications of 
CKD (Figure 1)1. 
 
Fig. 1 CKD classification based upon glomerular filtration rate and albuminuria 
 
2.2. Chronic kidney disease and cardiovascular disease 
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CKD has been showing an increased prevalence over the last 20 years and 
represents nowadays one of the main causes of death due to several 
comorbidities including cardiovascular diseases (CVD)2. CKD is characterized by 
frequent hospitalizations and consequent increase of healthcare costs. Early 
diagnosis and treatment of CKD using appropriate and low-cost therapies may 
prevent or at least slow the progression of renal disease, reducing the need of 
replacement therapy, clinical complications and associated high mortality rates3. 
Basing on the previous considerations, CKD is currently considered a major public 
health problem and the interest in CKD from the scientific community and health 
authorities particularly aroused by epidemiological data4. The last survey available 
showed that about 13% of the general adult population in the US has evidence of 
CKD and enter one of the five CKD stages identified according to K/DOQI 
classification5. In addition, the prevalence of CKD increases to 15-30% in the 
elderly and exceed 50% in patients with CVD and/or metabolic diseases, which 
are related to the steadily aging of population6. Moreover, in the next few years, a 
doubling of CKD patients due to the increasing incidence of hypertension, diabetes 
and metabolic syndrome is expected. The italian study CARHES (CArdiovascular 
Risk in Renal patients of the Health Examination Survey) has shown a prevalence 
of CKD of about 7%: this discrepancy compared to US data could be due to 
protective effects of genetic factors or to a different environment (i.e., 
Mediterranean diet)7. Other epidemiological studies have shown that, even in 
patients in stage III-IV CKD, mortality is mainly associated with CVD and it 
exponentially increases with the progression of renal damage8. The high risk of 
CVD in these patients implies that the incidence of death may even exceed (2 to 
50 times greater) the incidence of end-stage renal disease (ESRD), which is the 
culmination of CKD (need for replacement treatment with dialysis or kidney 
transplantation)9. In ESRD patients, the risk of major adverse cardiovascular 
events (MACE) and consequently of cardiovascular mortality is approximately 10 




Fig.2: age-standardized rate of MACE in patients with CKD 
 
2.3. CKD-related premature atherosclerotic disease 
Chronic inflammation plays a key role and seems to be closely related to 
accelerated atherogenesis processes. Inflammatory cytokines, adipokines and 
uremic toxins that are responsible for endothelial dysfunction and vascular 
calcification. Endothelial dysfunction represents the first clinical element to 
stimulate the atherosclerotic disease. This is important for subintimal accumulation 
of LDL, and their following modifications (aggregation, oxidation, and 
glycosylation) mediated by oxygen free radicals and hydrolytic enzymes secreted 
by macrophages and smooth muscle cells. Then, endothelial cells, as well as 
smooth muscle cells, express adhesion molecules on their surface and produce 
chemokines able to activate an inflammatory reaction with migration and adhesion 
of monocytes and T-cells in subintimal space11 . Modified LDLs are perceived as 
antigens, therefore they activate the immune response and are phagocytized by 
macrophages, once recognized by their scavenger receptors. Due to the 
impossibility of metabolizing the cholesterol, they transform into foam cells 
characteristic of the lipid striae (Fatty streaks). At this point the lesion progresses 
to enlarge evolving until the constitution of a complicated plaque, so defined as 
characterized by the high risk of rupture. Typically, in course of evolution from lipid 
stria to complicated plate, areas of calcification are formed also intimal. The 
adhesion of platelets and the formation of intramural clots, resulting from 




Fig. 3: Progression of atherosclerosis 
 
2.4. Senescence and non-traditional CKD-related risk factors 
The high prevalence of CVD in CKD patients is explained by accelerated 
senescence and pro-aging effects due to non-traditional CKD-related risk factors, 
combined with traditional risk factors (age, hypertension, diabetes mellitus, 






Senescence is the progressive deterioration of functional characteristics over time, 
due to the loss of the efficiency of physiological functions, and is strongly 
associated with a chronic inflammatory state, increased oxidative stress, 
mitochondrial dysfunction, necro-apoptosis. From a cellular and molecular point of 
view, CKD is currently considered a model of premature aging and frailty: indeed, 
several studies demonstrated that CKD patients are biologically older than their 
unaffected peers with marked effects on vascular, immunologic and cognitive 
senescence13. Of interest, all these biological processes are similar to those 
observed during aging. Vascular senescence is represented by the degeneration 
of the vascular structures (smooth muscle cells and endothelium), determining the 
alteration of the functional and mechanical properties with widespread media 
stiffening and alterations of the intima, associated with a state of chronic 
inflammation11,14. In this setting, selected molecules such as Klotho and Sirtuin1 
(Sirt1) that are known to be involved in the aging process are also significantly 
reduced in CKD patients. Klotho is able to increase resistance to oxidative stress 
through suppression of ROS generation: the deficit of Klotho gene expression in 
mice accelerates cellular senescence and death with an enhancement of vascular 
calcification and CKD incidence. Moreover, Klotho prevents endothelial 
senescence induced by uremia preventing NF-kB translocation, thus limiting 
systemic inflammation. Several water soluble and protein bound uremic toxins 
typical of CKD patients can induce methyltransferase protein expression leading to 
Klotho silencing through hypermethylation with a synergy in the induction of 
endothelial dysfunction and smooth muscle cell osteogenic differentiation 
responsible for calcification15–18. Silent information regulators Sirtuin proteins are 
deeply involved in cellular senescence processes through regulation of DNA 
repair, chromosomal stability and gene transcription. In particular, Sirt1 
upregulation suppresses age-related cardiac hypertrophy, apoptosis and 
senescence19. Sirt1 is increased after ROS generation as a protective mechanism 
and activation of sirtuins is known to increase resistance to metabolic, oxidative 
and hypoxic stress in different tissues including the kidney20,21. Of interest, some 
diet-associated antioxidant agents such as phenols are able to modulate Sirt1 
expression22: our research group previously reported that resveratrol and other 
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compounds such as tyrosol and caffeic acid are able to increase Sirt1 expression 
in human kidney cells interfering with senescence processes.  
 
2.4.2. Non-traditional CKD-related risk factors 
The identification of a group of non-traditional risk factors associated with CKD 
(albuminuria, anemia, disorders of mineral-bone metabolism, malnutrition, 
hyperhomocysteinemia, inflammation, endothelial dysfunction, oxidative stress, 
uremic toxins, volume overload), allowed to understand mainly the increased risk 
of CVD development in CKD patients: 
• OXIDATIVE STRESS: the increase of reactive oxygen species (ROS) is a 
typical feature of atherosclerotic disease and CKD, therefore persistent 
oxidative stress may be implicated in the pathogenesis of MACE in CKD23 
• ENDOTHELIAL DYSFUNCTION: Endothelial dysfunction, an alteration of 
normal endothelial function, which leads to the loss of structural and/or 
functional properties, is an important feature of CKD and is defined by the 
finding of impaired endothelial-dependent vasodilation due to inflammation, 
oxidative stress, dyslipidemia, hyperglycemia and hypertension23 
• INFLAMMATION: In CKD patients, especially dialysis patients, the 
inflammatory status represents a triggering factor for cardiovascular events, 
for example, many inflammatory biomarkers, such as IL-6, are found to have 
direct and indirect pro-atherogenic properties such as the ability to modulate 
bone remodeling 
• DISORDES OF MINERAL-BONE METABOLISM: Disorders of calcium and 
phosphate metabolism play an important role in the development of 
cardiovascular calcification. A serum phosphate level of 5.0 mg/dl or higher 
is associated with an increased risk of heart valve surgery. Vascular 
calcification is a highly regulated active process in which other factors, such 
as numerous mediators and cytokines also play a role, for example, 
hyperphosphatemia and altered level of FGF-23 have pro-inflammatory and 
pro-atherogenic effects.6 
• AGEs AND UREMIC TOXIN ACCUMULATION: Uremic toxins and the end 
products of intensive glycation (AGEs), which are collected because of non-
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enzymatic glycation and oxidative stress. They are metabolic, inflammatory, 
and oxidative stress biomarkers 
• ANAEMIA: Anemia is one of the main causes of left ventricular hypertrophy 
and consequently congestive heart failure in CKD6. The pathogenesis of 
anemia in CKD is complex, but a central feature is an inadequate availability 
of both erythropoietin and iron (Figure 4). The deficiency of iron available for 
erythropoiesis in CKD is linked to a relative block in iron absorption from the 
intestines and in reduced iron release from storage in macrophages and the 
liver. This iron blockade phenomenon is mediated by the master regulator of 
iron homeostasis, the liver-produced circulating protein hepcidin that is 
increased in presence of inflammation such as in CKD. Elevated hepcidin 
levels cause the internalization into cells of cellular iron transporter 
ferroportin, and consequently this maladaptive response blocks iron available 
for erythropoiesis. In addition, Iron deficiency is common in patients with 
CKD, occurring in ≥50% of patients with non–dialysis-dependent CKD and a 
greater percentage of patients receiving dialysis24. 
 
Fig. 4 Representation of the mechanisms underlying anemia of CKD 
 
• TYPE OF HEMODIALYTIC TREATMENT: Hemodialysis (HD) existed for 
more than 50 years and has extended the lives of millions of patients with 
renal failure worldwide. The  aim  of  the  HD  system  is  to  deliver  blood  in  
a  fail-safe  manner  from the patient to the dialyzer, enable the efficient 
removal of uremic toxins and excess fluid, and deliver the cleared blood back 
to the patient. The dialyzer provides countercurrent transfer of solutes and 
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fluid across a  semipermeable  membrane due to (1) the concentration 
gradient (diffusive transport) and (2) the hydrostatic pressure  gradient  
across  the  membrane  (convective  transport)  and  depends  on  
membrane  pore  size. Although the basic principles of HD are still being 
applied today, dialysis technology has improved markedly. Hemofiltration 
(HF) and hemodiafiltration (HDF) involve the removal of large fluid volumes 
from the patient, with the removed fluid replaced by substitution fluid. It is the 
use of substitution fluid that sets these techniques apart from simple 
ultrafiltration. HF is a convective elimination technique by  which  water  and  
solutes  from  the  blood  compartment  are  driven  solely  by  positive  
hydrostatic  pressure  across  the  dialyzer  membrane  into the filtrate 
compartment without the use of dialysate. As a result of solvent drag effects, 
small and larger solutes are eliminated at a rate depending on membrane 
features.  HDF  combines  diffusive  (HD)  and  convective (HF) solute 
transport using a high-flux membrane. Fluid is removed by ultrafiltration, and 
the volume of filtered fluid exceeding the volume to achieve target weight 
loss is replaced by ultrapure, non-pyrogenic infusion solution. Online HDF 
refers to the online production by  the  dialysis  machine  of  nearly  unlimited  
amounts  of  ultrapure,  nonpyrogenic dialysate, which is also used as 
infusion solution. High-volume  HDF  refers  to  an  effective  convection  
volume  of  at  least  20%  of the total blood volume processed25. In addition 
to the type of technique used, an extremely important role is related to the 
type of filter used. Considerable progress has been made in recent years, 
leading to the improvement of dialysis replacement therapy where the 
physical principles governing dialysis did not appear sufficient to optimize the 
process itself26. The membranes used during replacement treatment have 
evolved significantly: the initial membranes were formed from natural 
materials, such as cellulose, or simple synthetic compositions, like 
polysulfone, characterized by a symmetrical structure and good performance 
relative to the elimination of small molecules27. However, these membranes 
determined significant interactions with the complement pathway and 
immune response. The subsequent modification of hydroxyl groups on 
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cellulose membranes gave the same similar performance levels, but less 
bioactivity (diacetate cellulose membrane and hemophan). 
 
2.5. Inflammation and uremic toxins 
About 30% of pre-dialysis patients and 50% of ESRD patients demonstrate an 
increased inflammatory response, characterized by high levels of C-reactive 
protein (CRP) proportionally related to uremic toxin levels28. Inflammation plays a 
key role among the risk factors for MACE and the prognosis of CKD patients. In 
patients with CKD, it is frequent to find circulating high levels of mediators of 
inflammation, such as IL-1, IL-6, TNF-, C-reactive protein (CRP), fibrinogen, 
while albumin levels are low29. Not only there is an inverse correlation between 
levels of inflammatory mediators and GFR, but also CKD patients with a higher 
level of inflammatory cytokines, in particular IL-1, IL-6, TNF-, are those with lower 
chance of survival29. In addition, the accumulation of uremic toxins can interfere 
with biological functions. 
The European Uremic Toxin Work Group (EUTox) classifies the uremic toxins in 
three different groups30:  
• Water-soluble compounds with molecular weight < 500 Dalton: in this 
group we can find creatinine, urea, uric acid, which could be easily removed 
through the most common types of hemodialysis 
• Compounds with higher molecular weight (>500 Da), so-called middle 
molecules: ANP, 2-microglobulin, endothelin, FGF-23, ghrelin, light 
chains, IL-6,-8,-18, PTH, TNF, neuropeptide Y, lipids, and lipoproteins. 
The most representative is 2-microglobulin, removed by high cut-off 
dialyzer in diffusive, convective, or mixed modalities. 
• Liposoluble compounds and/or protein-bound toxins (PBUT): AGEs, 
homocysteine, indoxyl-sulfate, indolacetate, kynurenine, p-cresyl-sulfate, 
phenylacetate. Most solutes in this group have a low molecular weight, but 
some have features from medium molecules, such as leptin and retinol 
binding protein. Typical prototypes of PBUT are phenols and indoles. 
These compounds are difficult to remove from most of the dialysis 
techniques currently available. Their removal largely depends on the 
15  
balance between free and bound fractions; hemodiafiltration and adsorbent 
techniques appear to be more effective. 
Therefore, the association between traditional and non-traditional risk factors 
significantly influences cardiovascular mortality in uremic patients and the 
development of premature atherosclerotic disease. 
 
2.6. Endothelial dysfunction and vascular calcifications 
Inflammation is the main cause of the high cardiovascular risk in CKD patients. 
Inflammatory status is mediated by circulating uremic toxins which can directly or 
indirectly modulate vascular function and physiology.  Furthermore, dysregulation 
of calcium-phosphorus metabolism contributes to diffuse vascular calcifications31.  
 
2.6.1. Endothelial dysfunction 
Uremic toxins stimulate oxidative stress through the production of reactive oxygen 
species (ROS). This process brings to altered availability nitric oxide (NO) and 
consequent endothelium dependent vasodilation of blood vessels. Nitric oxide is 
important for maintenance vascular homeostasis, muscle tone, platelet adhesion, 
migration, and proliferation of vascular smooth muscle cells. Therefore, altered NO 
metabolism and increased oxygen free radicals cause endothelial dysfunction14. 
The loss of vascular compliance is mediated by uremic toxins which influence 
intracellular and intercellular signaling in endothelium and smooth muscle cells 
(Figure 5)32. 
 
Fig. 5 intracellular and intercellular signaling in endothelium and smooth muscle cells 
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Then, endothelial dysfunction is associated with an inadequate NO bioavailability, 
due to high level of circulating uremic toxins: this makes blood vessels less 
compliant and more prone to inflammatory injury. 
 
2.6.2. Vascular calcifications 
Endothelial dysfunction leads to the development of vascular calcifications. In 
addition, patients with CKD progressively lose the ability to adjust serum levels of 
calcium and phosphate. Altered calcium-phosphate metabolism stimulates 
transition of smooth muscle cells into osteoblast-like cells (Figure 6)33. 
 
Fig. 6: mechanism of vascular calcification 
 
Two genes are known to be strongly involved into vascular senescence and 
calcification: FGF23 and KLOTHO, respectively encoding for fibroblastic growth 
factor and its receptor. KLOTHO seems to have protective effects on vascular 
calcification, left ventricular hypertrophy and cellular senescence, while high levels 
of FGF23 stimulate hepatic production of inflammatory cytokines. 
Hyperphosphatemia, a specific feature of patient with end--stage renal disease 
(ESRD), both increases FGF23 and inhibits KLOTHO expression. The modulation 
of FGF23/KLOTHO levels leads to severe endothelial dysfunction, increased 




Fig. 7: KLOTHO and FGF23 in calcium-phosphate metabolism 
 
 
In addition, circulating uremic toxins have inhibitory effect on KLOTHO expression: 
this means a decreased inhibition of vascular calcifications and increased oxidative 
stress35. 
Therefore, uremic toxins and inflammatory cytokines removal through high--flux 
hemodialysis is nowadays considered the better therapeutic strategy to reduce the 
mortality rate for cardiovascular disease in patients with ESRD36. However, the 
relationship between uremic toxins and inflammation, endothelial dysfunction, 
reactive oxygen species and altered calcium--phosphate metabolism can only 
partially explain the development mechanism of cardiovascular injury in ESRD 
patients. Other biological factors seem to be deeply involved: uremic toxins, T-cell 
co-stimulatory molecules, extracellular vesicles, and activation of the complement 
cascade. 
 
2.7. T-cell co-stimulatory molecules 
T-cell co-stimulatory molecules are expressed on the surface of leukocytes and 
modulate T cell activation. Lymphocyte’s stimulation is mediated by binding of T cell 
receptor (TCR) to specific HLA--antigens present on the membrane of antigen-- 
presenting cells (APC). Moreover, lymphocyte co-stimulation is due to the 
interaction between different molecules expressed on APC and T-Cells. This causes 
T cell proliferation and differentiation and, consequently, the activation of the 
immune response. The lack of co-stimulation leads to T cell apoptosis and anergy. 
CD40/CD40L, B7/CD28, PD-1/PDL1 and ICOS/ICOSL are considered the most 
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relevant costimulatory pathways (Figure 8)37. These molecules are expressed not 
only on the surface of immune cell, but also on different epithelial and endothelial 
cells of different organs. Several studies reported the expression of CD40 and 
ICOSL on endothelial cells and vascular smooth muscle cells in the vessels, in the 
presence of inflammation and calcification. 
 
 
Fig. 8: T-cell co-stimulatory molecules 
 
 
2.7.1. ICOS and ICOSL 
ICOS is an inducible T-cell co-stimulatory molecule which needs the cooperation of 
other surface antigens (CD28 or CTLA-4) to activate T-lymphocytes. These three 
antigens are expressed on activated CD4+ and CD8+ T-cells. ICOS has a specific 
ligand, named ICOSL, expressed on B-cells, macrophages and dendritic cells. Its 
selective binding to ICOS stimulates T-cell proliferation and the production of 
different inflammatory cytokines such as IFN, IL-4, IL-10. ICOS seems also to be 
involved in atherosclerotic disease, then research on ICOS/ICOSL system could 





Fig. 9: tertiary structure of ICOS-ICOSL 
 
 
2.7.2. CD40 and CD40L 
CD40/CD40L pathway seems to be related to atherosclerosis and vascular injury. 
CD40 is a T-cell co-stimulator belonging to the TNF receptor superfamily. It is 
constitutively expressed not only on immune cell surface (B-lymphocytes, 
macrophages and dendritic cells), but also on endothelial cells, smooth muscle 
cells, platelets, and fibroblasts. The interaction between CD40 and its ligand 
CD154 (CD40 ”Ligand” or CD40L) on these different cells causes the production of 
interleukins (IL-1, IL-6, IL-8) and metallo-proteases, stimulating inflammatory 
response (Figure 10)37. 
 
Fig. 10: CD40/CD40-L co-stimulation pathway 
 
CD40 and CD40L are available in two different forms: plasma protein--bound type 
and soluble type. Soluble CD40L (sCD40L) is mainly produced by platelets: 
indeed, after platelet activation, CD40L is expressed on their surface and is cut by 
metallo-proteases to form the soluble fragment sCD40L. This molecule can bind 
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CD40 and activate the CD40/CD40L intracellular pathway. This leads to activation 
of inflammatory response, cytokine release and endothelial expression of adhesion 
molecules37. 
High levels of sCD40L can be found in patients with hypercholesterolemia, angina, 
and ischemic heart disease, and, locally, in unstable atheromatous plaques. 
Silencing of CD40/CD40L signaling can blunt atheromatous plaque progression, 
suggesting a key role of this pathway in the development of atherosclerotic 
complications39(p40). 
One of the largest clinical trial about cardiovascular risk in end-stage uremic patients 
(RISCAVID study) demonstrated that a concentration of sCD40L >7.6 ng/ml is 
associated with an increased incidence of cardiovascular and cerebrovascular 
events and mortality rate in hemodialysis patients. Therefore, chronic activation of 
the CD40/CD40L system can facilitate premature and accelerated 
atherosclerosis40. 
 
2.8. Extracellular vesicles 
Extracellular vesicles (EVs) are small lipid bilayer-delimited particles naturally 
released from a different cell in different ways. They have a fundamental role in 
intercellular communication, thanks to their ability to transfer proteins, lipids and 
nucleic acids to target cells41. We can distinguish three different subgroups, as 
reported in Figure 11 and 12. 
 
Fig. 11: EVs classification 
 
• Exosomes (40-130 nm), which arise from the endo-lysosomal compartment 
through the formation of multiple endoluminal vesicles, are released by 
exocytosis into the extracellular compartment. Exosomes are rich in 
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tetraspanine (CD9, CD63, CD81) and other molecules involved in signal 
transduction (TSG 101, RAB); 
• Microvesicles (or microparticles) differ from exosomes by their larger size 
(100-1000 nm) and formation mechanism, as they are released directly from 
the plasma cell membrane by gemmation, typically via a calcium-process-
dependent, which modifies the distribution of membrane phospholipids; 
• Apoptotic bodies, larger extracellular vesicles (50-5000 nm), are released 
into the extracellular environment during the apoptosis process. 
Vesicle contents may include nucleic acids (DNA, mRNA, rRNA, miRNA), cytokine 
receptors, cytoplasmic proteins, MHC molecules and lipids 
 
Fig. 12: Genesis and release of EVs from source cell 
 
EVs were found about 1950, when these mediators were initially called "platelet 
dust". In the following decades, several studies have allowed a better 
characterization of circulating EVs isolated by plasma and serum. Released EVs 
may remain in the extracellular space in proximity of the place of origin or may 
enter the biological fluids reaching distant sites. This may explain the presence of 
MVs in the plasma, urine, milk, and cerebrospinal fluid41. The bulk of MVs present 
in the circulation is derived from platelets (specific markers CD41a, CD6 and 
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GPIb), and in less extent from other blood cells and endothelial cells41. The 
release of EVs may be constitutive or consequent to cell activation by soluble 
agonists, by physical or chemical stress such as the oxidative stress and hypoxia, 
and by shear stress in different inflammatory diseases (i.e diabetes, hypertension, 
infections, neoplasm, chronic heart failure).  
Only in recent years has been recognized the role played by the EVs as mediators 
of intercellular communication, opening new scenarios regarding the mechanisms 
of cell-cell interaction, activation, and growth: this event can be induced by several 
stimuli coming from extracellular (hypoxia, oxidative stress) and intracellular space 
(cytoplasmic calcium concentration and alterations of cytoskeleton). Once 
released, they can interact with specific target cells through various mechanisms 
(Figure 13)42: 
• direct fusion of EVs with the cell cytoplasmic membrane and release of 
vesicular content into the cytoplasm; 
• endocytosis-mediated internalization and subsequent release of EVs content 
into the cell cytoplasm; 
• ligand/receptor interaction expressed on the cell surface and vesicular; 
• transfer of membrane receptors expressed by EVs to the surface of the target 
cell; 
• interaction with the extracellular matrix and release of their contents 
 
Fig. 13: Interaction between EVs and cellular targets 
 
Most EVs effects seem to be mediated by: 
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• the presence of different types of microRNA (miRNA) within the EVs, 
potentially transferable to target cells. MicroRNAs are small non-coding 
RNA sequences of about 22 nucleotides, already identified in different 
species (animal, plant, virus)43. It is now known that they have an important 
role in the progression of different diseases, especially in cancer diseases, 
but numerous evidences associate the action of microRNA also to the 
pathophysiology of myocardial infarction, cardiac hypertrophy, 
cardiomyopathy, arrhythmias, as well as in the regulation CVD-related 
epigenetic cell damage processes in CKD43,44 
• the effects of EVs, however, are also determined by the structures present 
on their surface. Indeed, EVs can express peculiar surface markers 
involved in inflammation, coagulative cascade activation and apoptosis, 
e.g., CD40L, TF, C5b9, ICOS42. Due to the presence of these same surface 
markers, plasma EVs seem to be effectively internalized, with different 
effects depending on the target cell: for example, in a study of Boulanger et 
al., in patient CKD, when affected endothelial cells, an increase in ROS was 
detected, when smooth vascular muscle cells, a faster osteoblastic 
transition was determined45. 
 
2.9. EVs in cardiovascular damage of CKD patients 
Plasma Endothelial-EV levels are higher in CVD patients than in healthy 
subjects46. The release of EVs seems to be mediated by numerous pro-
inflammatory elements such as cytokines, activated platelets or oxidized LDL; 
Moreover, the EVs themselves, appear to be involved in the modulation of 
inflammation by acting on several targets, both as pro-inflammatory and anti-
inflammatory factors such as cytokines, activated platelets or oxidized LDL45. EVs 
are involved in thrombus formation, presenting on their surface multiple platelet 
activation mediators, such as tissue factor (TF)47. In particular, EVs cause an 
increase in the intra-plaque TF concentration, resulting in activation of the 
coagulation cascade46. In addition, the EVs release pro-inflammatory cytokines 
(IL-1, IL-6, IL-8, TGFβ)42, induce an increase in the exposure of adhesion 
molecules and are involved in the activation of Platelet Activating Factor 
Receptors. The consequent endothelial activation induces the adhesion and 
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diapedesis of leukocytes and neutrophils, a crucial point in the atherosclerotic 
plaque formation process (Figure 14)48. In addition, the EVs are involved in 
inhibiting the release of nitric oxide by endothelial cells, without alterations in the 
expression of NO synthetase43,48. In patients with heart disease, the quantitative 
analysis of the circulating levels of endothelial-derived EVs after stimuli with 
acetylcholine showed that higher quantities of these EVs correspond to greater 
stiffness of the arterial wall, a lower capacity for vasodilation in response to the 
increase of blood flow and/or stimulation with acetylcholine42,45. 
 
 
Fig. 14: Representation of EVs in endothelial dysfunction and vascular calcification 
 
Similarly, in chronic kidney disease, high endothelial EVs levels correlate with the 
development of atherosclerosis and an increase in CVD. The high levels of EVs 
would be a consequence of the persistent inflammatory environment induced by 
uremia (uremic toxins, hyperphosphatemia, hypercalcemia, elevated levels of 
FGF23, decreased levels of KLOTHO)49. For example, it is precisely the high levels 
of phosphate, together with hypercalcemia and the presence of cytokines such as 
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TNF, that stimulate the secretion of EVs that release miRNAs favoring the 




Fig. 15: Simplification of EV role in vascular injury 
 
2.10. Complement system 
For decades, hemodialysis has been known to activate the complement system. In 
dialysis, complement activation is mainly caused by the interaction of blood with the 
membrane. Regardless of the efforts to improve biocompatibility, complement 
activation still occurs in HD, even with modern membranes. It has been 
hypothesized that complement activation leads to HD-induced inflammation and 
thereby increases the subsequent cardiovascular risk. However, the link between 
complement activation products and CV-events remains poorly characterized. 
Furthermore, previous experimental studies proposed a link between HD-induced 
complement activation, pro-inflammatory cytokines, and the coagulation system. 
Recently, complement activation prior to a HD session was associated with the 
occurrence of CV-events in HD patients and it has been shown that activation of the 
alternative pathway of the complement cascade (indicated as C3d/C3 ratio) during 
dialysis is linked to the development of CV-events. Daha et al. were the first to 
assess the relationship between intradialytic complement activation and subsequent 




Fig. 16: Correlation between C3 level and CV-events 
 
The same group also found that MBL was consumed in the event-free group, 
implying that this decrease is actually beneficial. In accordance, MBL has been 
proposed to be involved in the removal of atherogenic particles, thereby decreasing 
atherosclerosis. Higher MBL levels in HD patients were associated with protection 
against cardiovascular disease52. In addition, it has been found a rise in properdin 
levels in patients without CV events. Properdin, unlike other complement factors, is 
produced by leukocytes, predominately neutrophils. Therefore, the increase in 
properdin is presumably the result of leukocyte activation by the HD membrane 
leading to degranulation. Since, this rise was not observed in the CV-event group, 
it was speculated that this effect was due to properdin consumption by alternative 








The conclusions of Daha et al. were that intradialytic differences in complement 
activation may allow the identification of uremic patients at high risk to develop 
MACE. 
 
2.11. Renal replacement therapy and cardiovascular risk 
Because of the strong relationship between ESRD and cardiovascular risk, the 
different strategies of dialysis could be used not only for blood purification, but also 
to remove the above-mentioned molecules involved in inflammation, endothelial 
dysfunction, and oxidative stress. This would significantly improve the prevention 
of cardiovascular and cerebrovascular events in ESRD patients. 
Even though HDF seems to be the best strategy for blood purification due to an 
increased clearance of middle molecules and to reduce inflammatory parameters, 
the most recent randomized clinical trials did not prove HDF superiority over 
standard high flux HD in terms of incidence of MACE. A recent Japanese 
observational study registry demonstrated a considerable reduction of 
cardiovascular mortality in dialysis dependent people using a membrane with 
enhanced capacity of adsorption53, a process that helps to remove medium- and 
high molecular weight molecules, having a crucial role in the reduction of 
inflammatory mediators and consequently in the modulation of the development of 
cardiovascular damage. Among dialyzers with adsorption characteristics, 
polymethylmethacrylate (PMMA) membranes have the following features: better 
biocompatibility and high performance in removing uremic toxins. By lowering the 
uremic environment, PMMA membranes also improve the immune response of the 
CKD patient, reduce comorbidities, determine a superior ability to maintain muscle 
mass and protein, and reduce uremic itching.  
There are different PMMA dialyzer, in order to adapt to the different dialysis 
methods: 
• B3 PMMA series for low-flux hemodialysis  
• B1 PMMA series for high flow or low flow hemodiafiltration 
• PMMA series BKF, specific for the removal of high weight molecules 
(sCD40L)54 
• PMMA BGU series for removing medium-small molecules and uremic 
itching 
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• PMMA EAD series, for the removal of free light chains; this filter maximizes 
the absorption performance of light chains using a specific blood line set 
and a second BKF dialyzer; the result is a significant increase in the 
removal of light chains, working in bicarbonate dialysis standard mode. 
 
Moreover, these membranes have a very great biocompatibility (evaluated by 
WBC count, PLTS, C3 fraction).  
Other innovative filters have just been put on the market, such as the Theranova 
filter, a membrane optimized to remove medium and high weight molecules. The 
dialysis technique in which these filters are used does not change compared to the 
HD, however It cannot be used in HDF or HF. 
In addition, while convective and diffusive procedures clear and filter out low and 
medium molecular weight metabolites from the blood, adsorption can also remove 
high water-soluble molecular weight molecules as well as protein-bound uremic 
toxins (PBUT) independently from their molecular weight55. Basing on these 
considerations, PMMA dialyzers may remove metabolites involved in 
cardiovascular disease in people with ESRD, thus reducing the incidence of 
cardiovascular and cerebrovascular accidents53. 
In conclusion, recent clinical trials about cardiovascular risk in uremic patients 
underline the important role of sCD40L in atherosclerosis. In the same way, 
endothelial EVs can influence inflammatory status and nitric oxide concentration: 
they represent a reliable marker of endothelial dysfunction. The use of dialyzers with 
high adsorptive capabilities (e.g., PMMA) may improve uremic toxin removal 
efficiency, thus reducing cardiovascular mortality in dialysis patients. 
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3. Preliminary data and research activities during PhD program 
On this background, in the first and second years of PhD program we performed 
preliminary ELISA assay of sCD40L’s plasma levels in a group of hemodialysis 
patients (n=310), of which 175 (56.45%) patients had sCD40L values higher than 
7.6 ng/ml (Figure 18). 
 
Fig. 18: Distribution of patients with sCD40L values higher than 7.6 ng/ml in a cohort of 
hemodialysis patients (n=310) 
 
Subsequently, in a subgroup of these patients (n=10) and in a group of healthy 
subjects (n=10), we performed quantification and characterization of the plasma 
EVs, in vitro studies on human endothelial cells and smooth muscle cells to 
evaluate the biological role of EVs isolated from CKD plasma and analysis of 
microRNA content of plasma EVs. Preliminary data generated in UPO labs and 
external collaborators using Nanotrack particle analysis showed higher levels of 
circulating EVs in stage V CKD patients in chronic hemodialysis treatment in 
respect to healthy subjects (Figure 19).  
 






























FACS analysis of EVs isolated from plasma of patients with stage V CKD revealed 
the presence of surface antigens typical of platelets, mononuclear cells, and 
endothelial cells. Of interest, endothelial-derived EVs are not present in control 
healthy subjects. In addition, CKD plasma EVs express low levels of T and B cell 
antigens and exosomal markers, whereas they express high levels of class I HLA 
and molecules involved in inflammation, activation of the coagulation cascade and 
apoptosis such as CD40L, Tissue Factor (TF) and the terminal component of the 
complement cascade C5b9 or MAC (Figure 20).  
 
Fig. 20: Surface antigen expression of CKD plasma EVs 
 
After internalization, CKD plasma EVs exerted different biological effects within 
target cells. In endothelial cells, in respect to vehicle alone or EVs isolated from 
control healthy subjects, CKD EVs increased ROS production. In smooth muscle 
cells, in respect to vehicle alone or EVs isolated from control healthy subjects, 
CKD EVs increased osteoblast differentiation of SMC, a known marker of 
calcification (Figure 21).  
 
Fig. 21: (A) CKD plasma EV internalization in vitro within human endothelial cells (EC), 
artery smooth muscle cells (SMC) and (B) In EC, CKD EV increased ROS production and in 
SMC, CKD EV increased osteoblast differentiation, a known marker of calcification 
 
The preliminary analysis of microRNA content of CKD plasma EVs (using the web 
platform Protein Quest to design the pathways potentially involved in CKD plasma 
EV-induced endothelial dysfunction and SMC calcification) identified 5 microRNAs 
A B
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(miR-17-5p, miR-92a, miR-423-5p, miR-451a and in particular miR-223) that 
showed an increased expression in CKD plasma EV in comparison to EVs isolated 
from control healthy plasma. 
We also evaluated in this group of patients whether citrate-buffered dialysis 
improves HD efficiency, inflammatory parameters and chemerin-mediated 
microvascular injury. Patients were treated in sequence with acetate, citrate and, 
again, acetate-buffered dialysis solution (3 months per interval). At study 
admission and after each treatment switch, we evaluated dialysis efficacy and 
circulating levels of chemerin and different inflammatory biomarkers. In vitro, we 
stimulated EC and VSMC with patients' plasma and we investigated the role of 
chemerin as uremic toxin.  
Our investigation showed that citrate dialysis increased HD efficacy and reduced 
plasma levels of CRP, fibrinogen, IL6 and chemerin (Figure 22).  
 
Fig. 22: Citrate dialysis increased HD efficacy (A-B-C) and reduced plasma levels of CRP, 
fibrinogen, IL6 and chemerin (D-E-F-I) 
 
In vitro, patients' plasma induced EC and VSMC dysfunction. These effects were 
reduced by citrate-buffered solutions and paralleled by the decrease of chemerin 
levels. Consistently, chemerin receptor knockdown reduced EC and VSMC 
dysfunction. In conclusion, switching from acetate to citrate improved dialysis 
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efficacy and inflammatory parameters; in vitro, chemerin-induced EC and VSMC 
injury were decreased by using citrate as dialysis buffer. 
 
4. Aims of the study 
We think that lymphocyte co-stimulation pathways and EVs may at least in part fill 
the gap of knowledge in the pathogenic mechanisms of CKD-related CVD that 
may be only in part explained by the presence of middle/large molecular weight 
water soluble, and protein bound uremic toxins. Basing on previous literature and 
our preliminary results, we carried out an experimental study with the aim of 
analyzing the effect of the removal of the sCD40L by different dialysis treatments 
to identify the most effective and with a greater cardio-effect and vascular 
protection in the chronic uremic patient. In addition, in the second part of the study 
we evaluated the role of EVs in the modulation of cardiovascular damage of the 
chronic uremic patient. 
This study has three different purposes: 
 
• To identify a predictive value of sCD40L serum levels for incidence of 
cardiovascular events in a cohort of dialysis patients;;  
• To assess the role of sCD40L and its pathway, and compare the efficacy of 
two different types of dialyzers (PMMA BKF vs PS) in the removal of 
sCD40L and other molecules (double-crossover study); 
• To evaluate the effect of PS and PMMA-BKF on pro-inflammatory, pro-
atherosclerotic and pro-calcific uremic sera on endothelial cells and smooth 
human muscle cells in vitro, in particular by analyzing the role of the 
CD40/CD40L pathway; 
• To perform a characterization of CKD-EVs and an analysis of their role in 
conditioning endothelial dysfunction and vascular calcifications. 
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5. Patients and methods 
5.1. Clinical trial design 
5.1.1. Study population 
In this multicentric, prospective, double-cross-over study, we enrolled patients with 
end stage renal disease in hemodialytic treatment from 6 dialysis centers (A.O.U. 
Città della Salute e della Scienza di Torino, ASL Versilia, ASL CN1, ASL Asti, ASL 
Biella, ASL VCO). 
 
The inclusion criteria were the following: 
• Age from 18 to 75 years old 
• Patients in bicarbonate HD thrice weekly for at least 6 months 
• Patients with vascular access for hemodialysis allowing Qb > 250 ml/min 
 
Patients with neoplastic, acute, or chronic inflammatory disease (including HIV, 
HBV or HCV infection) and allergic to polysulfone/PMMA were excluded due to 
possible nonspecific increase of sCD40L serum levels. 
A written informed consent was obtained, and the study protocol reviewed and 
approved by local ethic committees. 
At the time of enrollment, demographic (age and gender) and clinical (start date of 
dialysis, diabetes, hypertension, dyslipidemia, nephropathy cause of ESRD and 
previous cardiovascular events) data of the whole population were entered into a 
centralized database.  
Serum sCD40L level were assessed at the time of the enrollment and during a 
median follow-up of 29 months. Cardiovascular and cerebrovascular events (acute 
myocardial infarction, congestive heart failure, severe peripheral vascular disease, 
and stroke) were registered.  
 
5.1.2. Patients with high cardiovascular risk 
In order to select patients with high cardiovascular risk, firstly we identified the 
sCD40L value with the best statistical performance to assess patients with highest 
cardiovascular risk of events – similarly to RISCAVID study – and secondly, we 
excluded people with sCD40L concentration lower than the cut-off value found.  
This selected cohort was randomized into two different groups to receive two 
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different type of hemodialysis treatment for an observational period of 9 months 
(Figure 23). Moreover, both groups were divided into two different hemodialysis 
programs, with two different dialyzers (RRT = Renal Replacement Therapy; PS = 
polysulfone; PMMA BKF = polymethylmethacrylate):  
 
• GROUP 1: 
T0 – T6 (months): RRT with PMMA BKF dialyzer 
T3 – T6 (months): RRT with PS dialyzer 
T6 – T9 (months): RRT with PMMA BKF dialyzer 
• GROUP 2: 
T0 – T3 (months): RRT with PS dialyzer 
T3 – T6 (months): RRT with PMMA BKF dialyzer 





Fig. 23: study protocol of the main project 
 
As a control group for clinical-laboratory evaluations, the selected cohort 
represents the control of itself, being a double cross-over study. As a control group 
for the comparison of in vitro analyses were enrolled n = 15 healthy subjects, 
corresponding by sex and age.  
Furthermore, during this study, using serum or plasma from the test population, 
further clinical or in vitro studies were carried out, such as: study of the effects of 
membranes on mass removal of sCD40L and PBUT, modulation of inflammation 
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following RRT with PMMA BKF or PS, expression of CD40L on the surface of EVs 
and sCD40L concentration after platelet stimulation with PBUT. 
5.2. Collection and storage of biological samples 
Blood samples have been collected through peripheral venous sampling: to 
separate the serum, whole blood samples have been centrifuged at 3500 g for 15 
minutes at room temperature; To separate the plasma, whole blood samples into 
EDTA anticoagulant were centrifuged at 1500 g for 15 minutes at room 
temperature. The plasma and serum samples thus obtained were stored at -80° C 
until their use. 
 
5.3. Laboratory measurements 
Peripheral blood samples from patients at the different time points in the study 
were used to: 
• Biochemical tests such as: PCR reactive C protein (mg/l), fribrinogen 
(mg/dl), ß2microglobulin (mg/l), ferritin (ng/ml), leukocyte count WBC 
(/microl), hemoglobin Hb (g/dl), platelets PLTs (/microl), hepcidin (ng/ml), 
parathormone PTH (pg/ml), albumin (g/dl), indoxil sulphate (ng/ml) 
• Quali-quantitative analysis of circulating EVs (concentration, content in 
miRNA, molecules expressed in membrane) 
In both groups, serum sCD40L levels, PCR, ß2microglobulin, Hb and Kt/V were 
assessed at the time of enrollment and every 3 months (T0 – T3 – T6 – T9), while 
every month the biochemical tests mentioned above were carried out. The Kt/V 
ratio is the parameter used to assess the adequacy of dialysis treatment, or the 
efficiency of the elimination of uremic toxins that accumulate in the body (usually 
the clearance of urea is considered); the ratio is calculated according to the 
formula of Gotch and Sargent. Hemoglobin (Hb) values are corrected by the 
erythropoietin resistance index because all patients enrolled were in erythropoietin 
therapy and this drug could alter the levels of hemoglobin. 
 
5.4. Mass removal of sCD40L and indoxyl sulphate 
We evaluate the sCD40L and indoxyl sulphate mass removal to obtain a 
quantitative measurement of solute removed from plasma using different 
membranes (PS vs. PMMA). This evaluation will be performed in group 2 patients 
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at the time T3 (at the switch from RRT with PS to PMMA BKF), according to the 
following scheme:  
• During the last week of RRT with filter in PS: degree of removal of sCD40L 
evaluated on Mondays and Fridays, at the first, second and fourth hours from 
the start of treatment.  
• During the first week of RRT with PMMA filter: degree of removal of sCD40L 
assessed on Mondays and Fridays, at the first, second and fourth hours from 
the start of treatment 





Body Volume before dialysis (ml) = 1000 x Body Weight before dialysis (Kg) x (1/13) 
Body Volume after 1/2 or 4h =  Body Weight before dialysis (ml) x HcT before dialysis 
(%)/HcT after 1/2 or 4h (%) 
 
To assess sCD40L concentration was used the following technique: dialysate was 
collected and then the concentration of the molecule was evaluated by ELISA test. 
To obtain a quantitative measurement of indoxyl sulphate removed in the different 
dialysis sessions with PMMA BKF or PS, also in this case the mass removal 
parameter has been calculated in patients, similarly to sCD40L, but the 
concentration of the molecule has been evaluated by mass spectrometers. 
 
5.5. Cell cultures 
- Human endothelial cells derived from the umbilical vein (HUVEC) were obtained 
from ATCC (PCS-100-010-ATCC USA). HUVEC were stored in EBM medium 
supplemented with 10% fetal calf serum and various endothelial growth factors. 
The experiments were carried out without FCS and after incubation with plasma of 
the patient diluted 1:10. They have subsequently been used in selected 
experiments, such as the evaluation of ROS production and the degree of 
activation of ROS (evaluated by the degree of adhesion of monocyte cells). 
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- Vascular smooth muscle cells (VSMC) were incubated at 37°C in 5% CO2 with 
MEM integrated with 1 mm of l-glutamine, 100 IU/ml of penicillin, 100 μg/ml of 
streptomycin and 10% of FBS. They were later used in selected experiments, such 
as the evaluation of osteoblastic differentiation and RUNX2 expression. 
- Monocyte cells were obtained from sound controls after isolation with Ficoll-
Hypaque density gradient (GE Health Care) and added to cell cultures in selected 
experiments. The monocytes were marked, to be evaluated in 
immunofluorescence, with green fluorescent marker.  
- Platelets: Platelet preparations (obtained from the Blood Bank) and laboratory 
PBUT have also been used to perform in vitro experiments assessing the 
correlation between sCD40L and PBUT concentrations.  
 
5.6. In vitro assessments using uremic sera 
- Endothelial activation: endothelial cells, after being incubated with the sera of 
uremic patients, were incubated with monocyte cells. The endothelial nuclei were 
highlighted with Propidium iodide dye (red), the monocytes were highlighted with 
membrane dye type PKH16 (green). The areas of fluorescence corresponding to 
monocytes were then counted. 
- Cellular calcification: intracellular calcium deposits were quantified by means of 
Alizarin red colouring. The muscle cells were cultured in 24-well plates and fixed 
with 4% paraformaldehyde in PBS for 45 minutes to 4°C. The cells were then 
washed in distilled water, exposed to Alizarin red (2% aqueous, Sigma Aldrich, St. 
Louis, MO) for 5 minutes, washed again and analyzed by inverted light 
microscopy. The cell lysates were analyzed in an automated spectrophotometer at 
a wavelength of 570 nm (Perkin Elmer), with detection of the relative degree of 
absorbance. 
- RUNX2: Positivity to RUNX2 was evaluated in immunofluorescence. An antibody 
was used that specifically detects RUNX2 produced by Covance (Princeton, NJ, 
USA). Positivity was also evaluated in FACS. The activation feedback of RUNX-2 
was also investigated by amplification of the same in qRT-PCR, although the 
results were not presented in this study. 
38  
- ROS: ROS production rate was measured using CM-H2DCFDA (Invitrogen™ 
Molecular Probes™, Thermo Fisher Scientific, Canada), a fluorescent probe. The 
endothelial cells grown in multi-well plates were washed twice with PBS to remove 
the medium. Then 0,5 ml of buffer containing 2 mM CM-H2DCFDA were added. 
Immediately after addition, fluorescence was measured in kinetic mode with 
excitation at 485 nm. This probe was used both for immunofluorescence reaction 
and in FACS for quantitative evaluation. 
- Immunofluorescence studies were conducted as follows: the cells were fixed with 
4% formaldehyde for 10 minutes at room temperature and then incubated 
overnight at 4°C with specific primary antibodies (and with the appropriate 
dilution). After incubation, fluorescence was detected using an Olympus Fluoview 
500 confocal laser scanning microscopy system with a 100x oil immersion 
objective at room temperature.  
 
5.7. sCD40L/CD40L ELISA 
The concentration of sCD40L/CD40L was determined using the following kit: 
HUMAN CD40L QUANTIKINE ELISA KIT (Red Systems, Miminneapolis, MN). 
The specific primary antibodies were already adhered to the plates provided in the 
kits. 
The protocol used was as follows: each well was filled with 100 ul of sample and 
the plate was incubated for 2 hours at 37°C. Then the sample was removed from 
each well and 100 ul of Detection Reagent A was added (prepared according to 
the indications in the kit with Detection A and Assay Diluent A with concentration 
1:100); after an incubation of 1 hour at 37°C, the Detection Reagent A was 
aspirated, and 3 washes were carried out with Wash Solution 1x (prepared 
according to the instructions in the kit). Then 100 ul of Detection Reagent B were 
added (prepared according to the indications contained in the kit with Detection B 
and Assay Diluent B with concentration 1:100) and left in incubation for 30 minutes 
at 37' C. 5 washes were performed with Wash Solution 1x. Finally, 90 ul of 3,3',5'-
Tetramethylbenzidine (TMB) Substrate Solution were added in each well, leaving it 
in incubation for 20 minutes, then the reaction was stopped by adding 50 ul of 
Stop Solution in each well. The absorbance of each sample was then measured at 
the spectrometer (Perkin Elmer) at a wavelength of 450 nm. 
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5.8. Cytometric analysis (FACS Analysis) 
Cytofluorimetric analysis was carried out using the GUAVA system (GUAVA Easy-
Cyte, Millipore). Endothelial cells were treated with sera taken from patients 
enrolled in the study at different times, and the production of ROS was evaluated 
in both immunofluorescence method to produce representative microphotographs, 
either by FACS analysis to quantify their production on a cellular level or to obtain 
a more precise quantitative analysis.  
Specifically, the production of reactive oxygen species (ROS) was evaluated by 
Image-iT® Detection Kit (Life Technologies, Carlsbad, CA, USA). The test is based 
on 5- (e-6) -carbase-2 ', 7'-dichlorodyfluorinated diacetate (carboxyH2 DCFDA), a 
compound that releases fluorescence after the association of ROS, as previously 
reported. The experiments were conducted according to the manufacturers' 
instructions; after incubation with selected stimuli, the cells were resourced with 
EDTA and analyzed by FACS. 
Muscle cells were treated with serums taken from patients enrolled in the study at 
different times, and the positivity for RUNX2 was evaluated in both 
immunofluorescence method to produce representative microphotographs, either 
by FACS analysis to quantify their positivity or to obtain a precise quantitative 
analysis. The method is like that for the evaluation of the production of reactive 
oxygen species. 
Isotype IgG antibodies, of murine derivation, associated with fluorescine (FITC) or 
phytooserin (PE) have been used as controls. The sera were incubated with each 
antibody or control isotype for 1 hour at 4°C and, after the necessary preparations 
(washing and centrifuging), were analyzed with FACS. The results obtained were 
expressed in % positivity for each marker analyzed. 
 
5.9. PBUT mass spectrometry (MS) analysis 
A mass spectrometry analysis has been performed for the PBUT concentration 
assessment; indoxyl sulphate has been selected as an example toxin and all 
assessments have been carried out on this. A mass spectrometer LTT Orbitrap 
(Thermo Scientific, Milan, Italy) with an electrospray ionization source (ESI) was 
used. LCcolumn effluent was fed into the ESI source using nitrogen sheath and 
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auxiliary gas. The capillary voltage and the optical voltage of the tube in the ESI 
source were maintained at 28 V and 70 V respectively. The source voltage was 
set to 3.5 kV (in both positive and negative ion mode). The capillary temperature 
was maintained at 270°C. The acquisition method used was previously optimized 
in tuningsections for the parent compound (capillary, magnetic lenses and variable 
octapolar voltages) to obtain maximum sensitivity. The analyses were performed 
using the full MS (range 50-1000 m/z) scan, MS2acquisition in positive ion mode, 
with a resolution of 30,000 (500 m/z FWHM) in FTMS mode (full transmission). 
The collision energy was set to 30% for all MS2acquisition methods. The 
acquisition range MS2 was between the cut-off values of the ion cage and the m / 
z value of the ion [M + H] +. The software X calibur (Thermo Scientif, Milan, Italy) 
is used both for the acquisition and for the analysis of data. 
 
5.10. Identification and characterization of microRNA content of plasma 
EV in CKD patients and evaluation of their pathogenic role 
5.10.1. Isolation and characterization of EVs 
For the isolation of EVs, peripheral blood samples stored in tubes with EDTA were 
centrifuged at 1300 g for 10 min at ambient temperature to obtain plasma. To 
isolate EVs, the plasma was subjected to additional 3 successive centrifuges at 
3300 g for 5 min at 4°C to remove debris. The samples thus obtained were then 
diluted 1:200 with 0.9% saline solution, sterile, and analyzed through the 
instrument Nanosight LM10 equipped with Nanoparticles Analysis System and 
NTA 1.4 Analytical Software, to evaluate concentration and size. The total number 
of EVs for each patient was obtained by multiplying the data provided by the 
instrument (EV/ml) by the dilution performed for the analysis. The part of the 
serum not used for the analyses, has been frozen at -80°C for any subsequent 
deepening. 
 
5.10.2. EVs cytometric analysis (Guava FACS Analysis) 
Cytometric analysis was carried out using the GUAVA system (GUAVA Easy-Cyte, 
Millipore). EVs from hemodialysis patients were incubated with antibodies directed 
against exosomes markers (CD9, CD81, CD63, CD86), platelets (Cd42b, CD62P, 
CD41), monocytes/macrophages (CD14, CD15), hematopoietic cells (CD34), 
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leukocytes (CD45), B cells (CD19, CD5, CD40), endothelial cells (CD144, CD31, 
CD105, CD146) and T cells (CD3) and antibodies against FAS-L, C5b-9, TF, 
ICOS and CD40L. Isotype IgG antibodies, of murine derivation, associated with 
fluorescine (FITC) or phytooserin (PE) have been used as controls. The EVs were 
incubated with each antibody or with the control isotype for 1 hour at 4 weeks C 
and, after the necessary preparations (washing and centrifuge), were analyzed 
with FACS. The internalization of EVs by endothelial and smooth muscle cells was 
evaluated qualitatively by indirect immunofluorescence and quantitatively by FACS 
analysis. 
 
5.10.3. Protein Quest 
To identify the most relevant microRNAs for cardiovascular disease in our 
patients, the literature has been analyzed with the appropriate web platform 
"Protein Quest" (PQ - Biodigital Valley, Aosta, Italy), which manages to 
automatically isolate what is required, screening all the information contained in 
the titles or abstracts of Pubmed, in the articles available as full text, in US patents 
and clinical trials. In addition, it classifies terminology through biomedical 
dictionaries and elaborates correlations between terms according to a hierarchical 
criterion. Using a proper search string it was then possible to select all the 
literature available on the web concerning vascular dysfunction and the problem of 
vascular calcifications in uremic patients. PQ then selected all microRNAs and 
related protein products described in the pathological processes of endothelial 
dysfunction and vascular calcification typical of advanced CKD. 
 
5.10.4. EVs RNA extraction and quantitative microRNA analysis (qRT-PCR) 
All the RNA contained in the EVs was extracted using the "All in one" method 
(Norgne, Thorold, ON, Canada). The RNA concentration and its purity were 
detected by the Nanodrop1000 spectrophotometer. Absorbance ratios of 260/280 
nm were considered with values between 1.8 and 2.0. The microRNAs detected 
by the protein quest were studied using the miScript Reverse Transcription Kit and 
the miScript SYBR Green PCR Kit (both of Qiagen). MicroRNA-specific Primers 
were used: hsa-mir-17-5p, -92-a, -223, -423-5p, -451a. RNU48 was used as a 
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reference control to normalize the data. RNA expression changes were calculated 
using 2-ΔΔCt method. 
 
5.10.5. CKD-EV internalization assay 
The cells were fixed with 4% formaldehyde for 10 minutes at room temperature 
and then counterstained with Hoechst (dilution 1:100) to identify the nuclei. By 
marking the Evs of CKD patients with a red fluorescent dye (PKH26 Sigma 
Aldrich), it was possible to observe the possible internalization within endothelial 
cells and smooth vascular muscle cells. After incubation, fluorescence was 
detected using an Olympus Fluoview 500 confocal laser scanning microscopy 
system with a 100-oil immersion objective at room temperature. 
 
5.10.6. Evaluation of CKD-EV effects in VSMC calcification 
To assess CKD-EV effects in VSMC calcification, intracellular calcium deposits 
were quantified by red-alizarin staining. The smooth muscle cells were cultured in 
24-well plates and fixed with 4% paraformaldehyde in PBS for 45 minutes at 4°C. 
The cells were then washed in distilled water, exposed to Alizarin red (2% 
aqueous, Sigma Aldrich, St. Louis, MO) for 5 minutes, wash again and analyzed 
by inverted light microscopy. Cell lysates were analyzed in an automated 
spectrophotometer at a wavelength of 570 nm, which delivered an absorbance 
parameter. 
 
5.11. Statistical analysis of patient data in the study 
The statistical processing of the data was carried out with PRISM system for MAC. 
Normality distribution was assessed preliminarily by q-q plot, Kolmogorov–Smirnov 
and Shapiro–Wilk tests. In the case of normal distribution, the quantitative 
variables were expressed by mean and standard deviation, if not by median, 
interquartile range (IQR). Categorical variables were expressed by absolute and 
relative frequencies. Differences between independent groups for continuous and 
categorical variables were estimated respectively by non-parametric Mann–
Whitney U-test and Fisher’s Exact test (or Chi-Square test). Differences between 
time points were evaluated by non-parametric Friedman test and, if statistically 
significant (p<0.05), differences between paired group (T0 vs T3, T3 vs T6, T6 vs 
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T9) were evaluated by non-parametric Wilcoxon signed-rank test with Bonferroni’s 
correction. Difference in cardiovascular events between groups positive or 
negative for sCD40L in the follow up period was evaluated by Kaplan-Meier 
analysis, Log-rank or Breslow test. Predictors for time to first cardiovascular event 
were evaluated by univariate and multivariate Cox regression. Predictors for 
cardiovascular events within 2 years were evaluated by logistic regression. 
 
5.12. Statistical analysis of in vitro studies 
The statistical processing of the data was carried out with PRISM system for MAC. 
The categorical variables were expressed as percentages, the continuous 
variables were expressed as means and standard deviation in the case of 
parametric variables, or median and interquartile ranges in the case of non-
parametric variables. Variance analysis (ANOVA) and Student-Newman-Keuls 
analysis were used when appropriate. For the experiments at the FACS was used 





6.1. Enrolled population and clinical-demographic features 
We initially selected 201 patients corresponding to the inclusion criteria from 6 
different hemodialysis centers (A.O.U. Città della Salute e della Scienza di Torino, 
ASL Versilia, ASL CN1, ASL Asti, ASL Biella, ASL VCO) and have been analyzed 
for different demographic and clinical features, as described in Table 1.  
 
Tab. 1: Baseline characteristics of initial population of 201 patients.  Data are presented 
as median (interquartile range – IQR) and percentage. 
Variables median (IQR) and percentage 
Age at enrollment (years) 68 (57 – 74) 
Age at dialysis initiation (years) 64 (53 – 71) 





Smoke history 37% 
Previous cardiovascular events 40% 
 
At the time of enrollment, the median serum concentration of sCD40L was 8.4 
(IQR 2.9 – 12.7) ng/ml. We registered cardiovascular and cerebrovascular events 
for a median follow-up of 29 (IQR 22 – 53) months. The minimum follow-up period 
was of 24 months. A total of 51 (25.4%) patients experienced a CV event during 
the whole follow-up: 44 events (21.9%) occurred within 24 months from 
enrollment. Moreover, 33 (16.4%) participants died, 9 of them because of a 
recognized cardiovascular cause. 
 
6.2. Identification of sCD40L predictive value for cardiovascular events 
Our first aim was to detect the best sCD40L cut-off value to identify patients with 
higher risk for MACE. We used 2 different ROC curves (Figures 24 and 25). 
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Fig. 24: ROC curve for global CV events 
 
A sCD40L plasma concentration equal to 7.7 ng/ml was determined to be the 
value with the best statistical performance to identify patients with shortest time to 
MACE (i.e with shortest event-free survival). 
 
 
Fig. 25: ROC curve for CV events within 2 years of follow-up 
 
Similarly, sCD40L plasma concentration equal to 7.8 ng/ml turned out to be the 
value with the best statistical performance to identify patients with highest risk of 
events within two years of follow-up. Using the cut-off value of 7.8 ng/ml, which 
was very closed to the RISCAVID study value, we divided our cohort into two 
















We compared these 2 groups for the principal demographic and clinical features 
(Table 2). 
 
Tab. 2 Comparison between patients with sCD40L < or > 7.8 ng/ml. Data are presented as 
median (IQR). Percentages are calculated on column totals. 
Variables 
Patients with sCD40L 
< 7.8 ng/ml 
Patients with sCD40L 
> 7.8 ng/ml 
p-value 
Age (years) 69 (57 - 75) 67 (56 - 74) 0.573 
HD vintage (months) 29.5 (14 - 60) 27 (15 - 50) 0.753 
Gender (male/female) 51/35 59/56 0.316 
Diabetes 37.2% 46.1% 0.249 
Hypertension 80.2% 86.8% 0.224 
Dyslipidemia 34.9% 42.6% 0.308 
Smoke history 34.9% 38.3% 0.659 
Previous CV events 37.2% 41.7% 0.562 
 
No statistical differences were found between the two groups about the major 
cardiovascular risk factors. Results of univariate and multivariate analysis with 
COX REGRESSION to identify risk factors for reduced event-free survival are 
described in the following Tables (Table 3 and 4). 
 
Tab. 3: Cox proportional hazards univariate analysis to identify risk factors for reduced 
event-free survival. 
Variables HR (95% CI) p-value 
sCD40L > 7.8 ng/ml 2.77 (1.45 – 5.29) 0.002* 
Age (years) 1.03 (1.01 – 1.06) 0.017* 
HD vintage (months) 1.00 (0.99 – 1.00) 0.672 
Gender (male/female) 1.42 (0.81 – 2.49) 0.227 
Diabetes 1.81 (1.04 – 3.15) 0.036* 
Hypertension 2.38 (0.86 – 6.63) 0.096 
Dyslipidemia 1.12 (0.64 – 1.96) 0.683 
Smoke history 1.04 (0.59 – 1.83) 0.902 







Tab. 4: multivariate Cox regression model to identify risk factors for reduced event-free 
survival 
Variables HR (95% CI) p-value 
sCD40L > 7.8 ng/ml 2.94 (1.53 – 5.66) 0.001* 
Age (years) 1.04 (1.01 – 1.06) 0.010* 
Diabetes 1.59 (0.91 – 2.77) 0.101 
 
In the univariate Cox proportional hazards regression model, median age, the 
presence of diabetes mellitus and sCD40L above the median value were 
associated with a significant increase in the risk of CV morbidity. With the 
multivariate Cox regression model, we demonstrated that median age and 
sCD40L concentration are independent risk factors for shortest time to events. 
Kaplan-Majer curve underlines the significant difference in CV event-free survival 
between two groups based on sCD40L level (Figure 26). 
 
 
Fig. 26: Kaplan-Majer curve. Green line refers to patients with sCD40L > 7.8 ng/ml;; Blue line 
refers to patients with sCD40L < 7.8 ng/ml 
 
As described in figure 17, after 25-30 months, event-free survival remains stable in 
both groups. Therefore, through a logistic regression we analyzed how sCD40L 
concentration could significantly influence the incidence of cardiovascular events 
over a period of 24 months. In the univariate regression, age, hypertension and 
sCD40L level were associated with high cardiovascular risk. The multivariate 
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regression demonstrated that age and sCD40L concentration are independent risk 
factors for CV events within two years (Tables 5 and 6). 
 
Tab. 5: Cox proportional hazards univariate analysis to identify risk factors for cardiovascular 
events over a period of 24 months 
Variables HR (95% CI) p-value 
sCD40L > 7.8 ng/ml 4.44 (1.94 – 10.16)  <0.001* 
Age (years) 1.05 (1.01 – 1.08)  0.006* 
HD vintage (months) 1.00 (0.99 – 1.01) 0.998 
Gender (male/female) 1.26 (0.64 – 2.47)  0.511 
Diabetes 1.68 (0.86 – 3.29)  0.131 
Hypertension 5.00 (1.15 – 21.82) 0.032* 
Dyslipidemia 0.97 (0.49 – 1.92)  0.918 
Smoke history 0.86 (0.43 – 1.73)  0.672 
Previous CV events 1.52 (0.77 – 2.98)  0.226 
 
Tab. 6: multivariate Cox regression model to identify risk factors for cardiovascular events over a 
period of 24 months 
Variables HR (95% CI) p-value 
sCD40L > 7.8 ng/ml 4.97 (2.10 – 11.73)  <0.001* 
Age (years) 1.05 (1.01 – 1.09)  0.007* 
Hypertension 3.28 (0.71 – 15.06)  0.127 
 
6.3. Comparative analysis of the efficacy between PMMA BKF and PS in 
patients with high cardiovascular risk (double-crossover study) 
From this population we enrolled n = 54 patients with increased cardiovascular risk 
considering values of sCD40L > 7,8 ng/ml cut-off (value very closed to the 
RISCAVID study). During the study, 6 patients dropped-out because of different 
causes: 1 death, 4 kidney transplants, 1 transfer to other dialysis center. Two final 
groups of 24 patients completed the study.  
The general characteristics of this cohort are described in Table 7 and in Figure 
27: it was composed mainly of females (57.1%), mainly of Caucasian ethnicity 
(96.4%), with a mean age of 50,2 years. All the cohort patients had been in 
bicarbonate dialysis replacement therapy for at least 6 months, with an average 








Tab. 7 General features of 48 enrolled patients. Data are presented as mean ± standard 














Fig. 27: Prevalence of chronic kidney disease causes in the general study population  
 
The following data are the clinical-laboratory parameters at the T0. The blood 
chemistry profile of the study court was characterized by inflammatory indices 
above normal values (CRP 4,90  6,28 mg/L; β2microglobulin 16,87  8,32 mg/L), 





Socio-demographic variables Male 12/28 (42.9%) 
Age (years) 50,29 ± 16,3 
Caucasian 27/28 (96,4%) 
General clinical variables Weight (Kg) 69,3 ± 13,65 
Ipertension 23/28 (82.1%) 
Diabetes 12/28 (42.9%) 
Cardiovascular disease 10/28 (35.7%) 
Dialysis clinical variables Vascular access (FAV) 22/28 (78.6%) 
Dialytic vintage (months) 47,7 ± 20 
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Tab. 8 Clinical-laboratory characteristics of the cohort at T0  
Clinical-laboratory parameters Mean ± SD 
CRP (mg/L) 4,90 ± 6,28 
Fibrinogen (mg/dL) 350,02 ± 109,00 
β2microglobulin (mg/L) 16,87 ± 8,32 
Ferritin (ng/mL) 270,87 ± 200,08 
WBC (/microL) 5541,05 ± 1190,30 
Hb (g/dL) 10,5 ± 1,20 
PLTs (/microL) 240.093,42 ± 32.000,3 
PTH (pg/mL) 378,30 ± 300 
Albumin (g/dL) 3,50 ± 0,05 
Kt/V 1,18 ± 0,22 
sCD40L (ng/mL) 12.11 ± 3.32 
Indoxil sulphate (microg/mL) 15,93 ± 16.84 
 
No patient developed local or systemic acute infection, autoimmune or neoplastic 
pathologies during the follow up.  
As a control group for the remaining clinical-laboratory evaluations, the selected 
cohort represented control of itself, being a double cross-over study.  
As a control group for the comparison of in vitro analyses were enlisted n = 15 
healthy subjects, corresponding by sex and age.  
The selected population was divided into two groups of the same number (n = 24) 
and as described in detail in "Patients and Methods". 
 
6.3.1. Effects of PMMA BKF and PS on inflammatory molecules (CRP, 
β2microglobulin) 
The evolution of serum levels of CRP and β2microglobulin in the two groups was 
evaluated at times T0 (zero time), T3 (three months), T6 (six months), T9 (nine 
months), to assess the effects of the two different dialysis methods on analytes.  
The analysis of variance did not show any significant differences among the 2-







Tab. 9 paired analysis of CRP removal by PMMA vs PS at different time points within two 
groups. No significant differences found with Friedman Test (p = 0.09 and 0.40, group 1 and 
2 respectively) 
CRP (mg/dl) 
 Group 1 Median (IQR) Group 2 Median (IQR) 
T0 0.91 (0.30 – 4.72) 0.90 (0.21 – 3.25) 
T3 0.83 (0.28 – 4.42) 0.60 (0.22 – 4.05) 
T6 1.00 (0.48 – 1.54) 0.50 (0.17 – 4.60) 
T9 0.57 (0.22 – 1.67) 0.80 (0.25 – 3.00) 
 
Tab. 10 paired analysis of β2microglobulin removal by PMMA vs PS at different time points 
within two groups. No significant differences found with Friedman Test (p = 0.82 and 0.86, 
group 1 and 2 respectively) 
β2microglobulin (ng/ml) 
 Group 1 Median (IQR) Group 2 Median (IQR) 
T0 18.7 (16 – 27.5) 25 (15.7 – 30.6) 
T3 20.2 (15.4 – 31) 26.9 (15 – 29.9) 
T6 19.7 (11.8 – 29) 26.4 (15.9 – 32.9) 
T9 25.4 (11.8 – 31) 20.8 (16.3 – 34.6) 
 
6.3.2. Effects of PMMA BKF and PS on hemoglobin (Hb) and Kt/V 
The variations Hb and Kt/V in the two groups were evaluated at different time 
points (T0-T3-T6-T9), to assess the effects of the two different membranes.  
The analysis of variance did not show any significant differences among the 2-
study group (Tab. 11 and 12). 
 
Tab. 11 paired analysis of Hb at different time points within two groups. No significant 
differences found with Friedman Test (p = 0.45 and 0.33, group 1 and 2 respectively) 
Hemoglobin (g/dl) 
 Group 1 Median (IQR) Group 2 Median (IQR) 
T0 10.80 (9.45 – 11.95) 11.20 (10.95 – 11.60) 
T3 11.00 (9.70 – 11.57) 11.10 (9.95 – 11.60) 
T6 10.03 (0.48 – 12.23) 11.20 (10.25 – 11.65) 
T9 11.25 (10.60 – 11.78) 10.80 (9.80 – 12.05) 
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Tab. 12 paired analysis of Kt/V changes at different time points within two groups. No 
significant differences found with Friedman Test (p = 0.40 and 0.29, group 1 and 2 
respectively) 
Kt/V 
 Group 1 Median (IQR) Group 2 Median (IQR) 
T0 1.32 (1.11 – 1.59) 1.36 (1.26 – 1.60) 
T3 1.34 (1.19 – 1.59) 1.36 (1.26 – 1.71) 
T6 1.30 (1.16 – 1.57) 1.33 (1.16 – 1.58) 
T9 1.29 (1.21 – 1.48) 1.40 (1.19 – 1.63) 
 
6.3.3. Effects of PMMA BKF and PS on sCD40L, ICOS and hepcidin  
Serum levels of sCD40L, ICOS and hepcidin were evaluated in the two groups at 
the times T0, T3, T6 and T9 to assess the effect of the two different dialytic 
membranes.  
The variance analysis showed a strong statistically significant difference in both 
sCD40L and hepcidin levels in the 2-study groups, and the Wilcoxon Signed 
Ranks Test confirmed that the use of PMMA dialyzer was constantly associated 
with a significant reduction of sCD40L and hepcidin concentration, which 
increased again whenever PS was re-started (Table 13-14 and Figure 18-19). 
 
Tab. 13 paired analysis of sCD40L concentrations at different time points within two groups. 
Statistically significant differences were found in the variance analysis with Friedman Test 
(p < 0.0001 in both groups) and Wilcoxon Signed Ranks Test 
sCD40L (ng/ml) p-value 
(Wilcoxon test)  T0 T3 T6 T9 
Group 1 
10.47  
(8.74 – 15.07) 
2.93  
(1.63 – 4.05) 
6.70  
(5.38 – 8.53) 
2.25  
(1.10 – 3.58) 
T3-T0 p < 0,0001* 
T6-T3 p < 0,0001* 
T9-T6 p < 0,0001* 
T9-T0 p < 0,0001* 
Group 2 
10.70  
(8.86 – 13.30) 
11.50  
(8.70 – 13.50) 
3.10  
(1.90 – 4.50) 
6.80  
(4.40 – 9.60) 
T3-T0 p = 0,626 
T6-T3 p < 0,0001* 
T9-T6 p < 0,0001* 
T9-T0 p = 0,001* 
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Fig. 28: Box plot (median and IQR) for sCD40L concentrations at different time points within 
two groups.  
 
Tab. 14 paired analysis of Hepcidin concentrations at different time points within two 
groups. Statistically significant differences were found in the variance analysis with 




























Hepcidin (ng/ml) p-value 
(Wilcoxon test)  T0 T3 T6 T9 
Group 1 
63.1  
(43.7 – 86.3) 
25.3 
(11.3 – 50.1) 
38.8 
(13.5 – 75.5) 
19.4 
(4.1 – 51.7) 
T3-T0 p < 0,0001* 
T6-T3 p = 0,009* 
T9-T6 p = 0,004* 
T9-T0 p = 0,001* 
Group 2 
60.2  
(40.0 – 81.6) 
73.3  
(48.4 – 92.2) 
21.2  
(16.4 – 59.9) 
59.8  
(31.4 – 79.1) 
T3-T0 p = 0,153 
T6-T3 p < 0,0001* 
T9-T6 p = 0,005* 
T9-T0 p = 0,294 
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Fig. 29: Box plot (median and IQR) for Hepcidin concentrations at different time points 
within two groups.  
 
Concerning ICOS concentration, the analysis of the variance did not show any 
significant differences among the 2-study group (Table 15) 
 
Tab. 15 paired analysis of sICOS concentration changes at different time points within two 
groups. No significant differences found with Friedman Test (p = 0.93 and 0.15, group 1 and 
2 respectively) 
sICOS (ng/ml) 
 Group 1 Median (IQR) Group 2 Median (IQR) 
T0 1.70 (1.20 – 1.85) 1.60 (1.30 – 1.80) 
T3 1.70 (1.30 – 1.70) 1.70 (1.20 – 1.80) 
T6 1.50 (1.45 – 1.70) 1.70 (1.30 – 1.80) 
















Group 1 Group 2








To confirm the effect of the dialytic membrane on the reduction of serum levels of 
sCD40L, the mass removal was calculated in a subgroup of n = 10 patients from 
Group 2, according to the modalities and timing illustrated in "Patients and 
Methods". 
 In patients, when undergoing dialytic treatment with membrane in PS, the 
calculation of mass removal had highlighted that the amount of sCD40L removed 
from the plasma respectively after 1, 2, 4 hours was equal to: 10050,30 ± 510,08 
ng, 15050,01 ± 506,00 ng and 30105,00 ± 602,20 ng in the first session (Monday) 
and 9014 ± 794,08 ng, 10100,01 ± 250,09 ng and 29770,09 ± 252,00 ng in the 
second session (Friday).  
In patients, when undergoing dialysis treatment with membrane in PMMA BKF, the 
calculation of mass removal showed that, respectively after 1, 2, 4 hours, the 
amount of sCD40L removed from the plasma was equal to: 27000,07 ± 690,05, 
39044,05 ± 500,05 and 58976,07 ± 502,01 ng in the first session (Monday), 
whereas 20100,04 ± 502,00, 40089,00 ± 400,02 and 60040,55 ± 365,02 ng in the 
second session (Friday) (Table 14, Figure 30). The amount of sCD40L removed by 
PMMA after the fourth hour was almost three-fold higher than the one removed by 
PS. All the data obtained were statistically significant (p<0.05). 
 
Tab. 14 Comparison of sCD40L mass removal in Group 2, 1-2-4 hours after starting 
hemodialytic treatment with PS or PMMA BKF, respectively in the following sessions: last 
Monday and Friday before shift at PMMA BKF, first Monday and Friday treatment with 
PMMA BKF membrane 
Mean mass removal of sCD40L (ng) 
Membrane 
Monday Friday 
1° hour 2° hour 4° hour 1° hour 2° hour 4° hour 
PS 






























Fig. 30: sCD40L mass removal rate during Monday and Friday HD sessions (PMMA vs. PS): 
sCD40L serum levels were evaluated after 1-2-4 hours from the start of dialysis 
 
6.3.5. Effects of PMMA BKF and PS on PBUT (Indoxyl sulfate) mass 
removal  
To assess the effect of dialytic membrane on PBUT mass removal, the mass 
removal of indoxyl sulphate (IS), used as an example toxin of this category, has 
been calculated in a subgroup of n = 10 patients of Group 2, in accordance with 
the procedures and timetables described in "Patients and Methods". In patients, 
the amount of IS removed from plasma respectively after 1, 2, 4 hours of treatment 
with membrane in PS, was respectively 5000,88 ± 500,08, 15000,11 ± 512,00 and 
19005,00 ± 612,20 ng in the first session (Monday), while 4516,00 ± 500,27, 
14900,01 ± 470,36 and 22370,00 ± 351,00 ng in the second session (Friday). In 
patients, the amount of IS removed from plasma respectively after 1, 2, 4 hours of 
treatment with membrane in PMMA BKF, was equal to: 27000,07  690,05, 
39044,05  500,05 and 58976,07  502,01 ng in the first session (Monday), 
whereas 20100,04  502,00, 40089,00  400,02 and 60040,55  365,02 ng in the 
second session (Friday) (Table 15, Figure 31). All the data obtained are significant 
with a p value of 0,05. 
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Tab. 15 Comparison of IS mass removal in Group 2, 1-2-4 hours after starting hemodialytic 
treatment with PS or PMMA BKF, respectively in the following sessions: last Monday and 
Friday before shift at PMMA BKF, first Monday and Friday treatment with PMMA BKF 
membrane 
Mean mass removal of IS (ng) 
Membrane 
Monday Friday 
1° hour 2° hour 4° hour 1° hour 2° hour 4° hour 
PS 




























Fig. 31: IS mass removal rate during Monday and Friday HD sessions (PMMA vs. PS): IS 








6.3.6. Relationship between sCD40L and IS levels  
A trend to a correlation between serum levels of sCD40L and IS, a PBUT, was 




Fig. 32: relationship between sCD40L and IS 
 
6.4. Concentration of sCD40L after platelet stimulation with PBUT in vitro 
To further assess the relationship between PBUT and sCD40L, platelet stimulation 
studies were carried out in vitro. 
Five laboratory platelet pools were used, each of which was incubated at 
increasing levels at a known concentration of indoxyl sulphate (0.1-1-10 
microgr/ml), and sCD40L concentrations were measured at 1 hour and 24 hours. 
Incubating platelets with increasing doses of PBUT, the levels of sCD40L 
progressively increased, at the surveys carried out both after 1 hour and after 24 
hours, reaching the statistical significance only after stimulation with a 
concentration of PBUT > 10 microgr/ml, with an associated sCD40L value of 
4,9±0,71 ng/ml after 1 hour and 6,8±0,80 ng/ml after 24 hours (Table 16, Figure 
33). 
 
Tab. 16 sCD40L concentrations after 1 hour and 24 hours from stimulation of platelet 
supernatants with increasing doses of IS  
 IS (microg/mL) 
0.1  1  10  
sCD40L a 1h (ng/mL) 2,8 ± 1,30 3,6 ± 0,91 4,9 ± 0,71 
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sCD40L a 24 h (ng/mL) 4,7 ± 1,27 3,8 ± 0,93 6,8 ± 0,80 
 
Fig. 33: sCD40L concentrations after incubation of platelet pools with increasing doses of 
IS, respectively measured after 1 hour and 24 hours of stimulation 
 
6.5. In vitro modulation of endothelial dysfunction and vascular 
calcifications following RRT with PMMA BKF or PS  
In vitro studies were also carried out to assess the association between circulating 
levels of sCD40L and markers of endothelial dysfunction and vascular 
calcification, such as free oxygen radicals (ROS), degree of monocyte adhesion 
and degree of osteoblastic differentiation by smooth vascular muscle cells. 
 
6.6. In vitro assessment of ROS levels in endothelial cells 
This evaluation was aimed to identify in Group 1 and 2 the percentage of ROS 
(Reactive Oxygen Species) produced at T0 and T3 checkpoints. Sera of n = 28 
uremic patients were incubated with endothelial cells, to assess the degree of 
activation and subsequent production of ROS. 
In Group 2 the mean ROS expression at T0 was 60,30  5,16 %, with a reduction 
to 50,40  6,30 % after 90 days (T3) of PS membrane therapy.  
In Group 1 the mean ROS expression at T0 was 60 ± 4.12%, with a reduction to 
30,21 ± 5,05% after 90 days (T3) of membrane therapy in PMMA BKF (Figure 34). 
The difference in the latter case was significant, with p-value < 0,05. By 




Fig. 34: Mean percentage of oxygen radicals (ROS) produced by endothelial cells incubated 
with serum of Group 1 and 2 patients, at times T0 (day 0) and T3 (day 90). In the box, an 
example image of the positive indirect immunofluorescence reaction for the presence of 
ROS (in green) 
 
6.7. In vitro assessment of the degree of adhesion of monocytes to 
endothelial cells 
Sera of n = 28 uremic patients were incubated with endothelial and monocyte 
cells, to assess the degree of endothelial activation and monocyte adhesion to 
endothelial cells. 
In Group 2 the number of monocytes adhering to the endothelium activated per 
field at time T0 was 118  5, with a reduction to 111  8 monocytes adhering after 
90 days (T3) of PS membrane therapy.  
In Group 1 the number of monocytes adhering to the endothelium activated per 
field at time T0 was equal to 120  4, with a reduction of up to 17  5 monocytes 





the latter case, the difference was significant (p-value < 0,05). By comparison, the 
controls showed mean values of 17  3,5. 
 
 
Fig. 35: Mean number of monocytes adhering to endothelial cells after stimulation with sera 
of Group 1 and 2 patients, at T0 and T3. In the panels, illustrative images that compare the 
different number of monocytes (green) adhering to the endothelium, stimulated by the sera 
of patients in RRT with PS or PMMA BKF membrane, at T0 (day 0) and T3 (day 90) 
 
6.8. In vitro assessment of the degree of osteoblastic differentiation of 
smooth muscle cells 
This evaluation was aimed to identify in both groups the reduction of osteoblastic 
differentiation by smooth muscle cells at T0 and T3. 
In Group 2 the number of cells positive to the red alizarin dye at T0 was 93  5, 
with a reduction to 80  13 after 90 days (T3) of membrane therapy in PS.  
In Group 1 the number of cells positive to the red alizarin dye at the time T0 was 
904, with a reduction of up to 40  5 after 90 days (T3) of membrane therapy in 




Fig. 36: Comparison of the mean value of smooth muscle cells positive to the Alizarin red 
dye (osteoblastic differentiation marker) in patients in PS or PMMA BKF filter therapy, at T0 
and T3. In the box, the sample images compare the effect on smooth muscle cells 
determined by the control serum with that taken after RRT procedure with PS and PMMA 
BKF, in correspondence of T0 (day 0) and T3 (day 90) 
 
Finally, the expression of RUNX-2 was investigated by the smooth muscle cells 
used in the previous evaluation, incubated with the sera of day 0 (T0) and 90 (T3) 
of both Group 1 and Group 2. 
In Group 2 the percentage of expression of RUNX-2 in smooth muscle cells at the 
time T0 was 55,50 ± 4,00%, with a reduction to 47,70 ± 4,70 % after 90 days (T3) 
of membrane therapy in PS.  
In Group 1 the percentage of expression of RUNX-2 in smooth muscle cells at T0 
was 60,2  5,56 %, with a reduction to 23,35  6,5 % after 90 days (T3) of 
membrane therapy in PMMA BKF (Figure 37). The difference was significant, with 
p-value < 0,05. 
Increased expression of RUNX-2 was also detected at the gene level via qRT-







Fig. 37: Mean percentage of activation of RUNX-2 within smooth muscle cells incubated with 
sera of Group 1 and 2 patients, at T0 (day 0) and T3 (day 90). Above, an example image of 
the positive indirect immunofluorescence reaction for RUNX-2 (in green) 
 
6.9. EVs isolation and characterization 
We performed a first characterization of the EVs present in the plasma of the study 
cohort at T0, in comparison with healthy subjects. 
The results of this analysis showed an increased plasma concentration of EVs in 
uremic patients (1,3x1012 ± 1,25x1011 particles/ml), compared with the healthy 
controls (4,8x1011 ± 1,0x1011 particles/ml). This difference was significant (p < 
0,05) (Figure 38). 
 
Fig. 38: Concentration of EVs found in patients with chronic kidney disease (CKD) by 
Nanotrack Analysis (Nanosight). On the right, sample graph of Nanosight analysis that 
analyzes the dimensions and relative concentrations of Evs (Ex = 10x) 
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The EVs identified were then characterized using the Nanosight and FACS 
analysis to assess some of the molecules most expressed on the membrane and 
thus their cell source. 
There is no statistically significant difference in the cell source of CKD-EVs in 
comparison with healthy controls, except for endothelial EVs (p<0,05). (Table 17, 
Figure 39) 
 
Tab. 17 Mean positivity percentages for specific markers of different cell types in CKD 
patients in bicarbonate dialysis compared with healthy controls 
Specific markers of source cells 
% of positivity 
CKD-EVs Healthy-EVs 
Platelet (CD42b, CD62P, CD41) 50,30±2.50 53,60±5,05 
Monocyte (CD14, CD15) 21,30±0,05 24±3,80 
T lymphocyte (CD3) 0,13±0 0 
B lymphocyte (CD19, CD5, CD40) 1,43±1,03 0.1±0,2 
Endothelial cells (CD144, CD31, CD105, CD146) 27,34±2,75 17,04±3 
 
 
Fig. 39: Origin of EVs obtained from FACS analysis based on the type of membrane cell 
markers expressed in CKD patients in bicarbonate dialysis in comparison with healthy 
controls 
 
Subsequently, we evaluated the surface expression of specific markers involved in 
apoptotic, inflammatory, and pro-coagulatory phenomena. 
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The CKD-EVs showed on their surface the expression of molecules involved in 
apoptotic, inflammatory, pro-coagulatory and complement activation phenomena 
such as Tissue Factor, C5b-9, CD40L, ICOS, FAS-ligand, NGAL, Class I HLA and 
different types of protein in the selectin and integrin family (Table 18, Figure 40). 
The statistical significance has always been reached (p < 0,05). 
 
Tab. 18 Mean positivity percentages for different apoptotic, inflammatory, and pro-




% of positivity 
CKD-EVs Healthy-EVs 
CD40L 7,50 ± 2,40 2,23 ± 0,01 
Tissue Factor 25,44 ± 4,05 25,00 ± 2,08 
C5b-9 10.01 ± 3,00 3,34 ± 3,00 
ICOS 11,39 ± 0,03 1,39 ± 1,03 
FASL 13,37 ± 4,75 2,73 ± 1,75 
 
 
Fig. 40: Expression of surface markers involved in inflammation processes, apoptosis, 
coagulation and complement activation in CKD patients in bicarbonate dialysis compared 





6.10. Characterization of microRNA in CKD-EVs  
Through the Protein Quest platform, we identified the 5 most common miRNAs 
involved in endothelial dysfunction and vascular calcification, with known pro-
apoptotic and anti-angiogenic abilities (miR17a-5p, miR92a, miR423-5p, miR451, 
miR223). Currently, we’re performing a relative quantification by RT-PCR of the 
expression of the 5 miRNA of interest. 
 
6.11. Biological effect of EVs on endothelial cells and VSMC  
In order to assess the biological activity of the uremic EVs we evaluated - by 
immunofluorescence and FACS analysis - the internalization of EVs within 
endothelial cells and VSMC using a pool of EVs from the surviving samples. As 
showed in Figure 42, EVs were internalized by EC and VSMC compared to 
controls. 
 
Fig. 42: In the panels, immunofluorescence reaction illustrating the internalization of EVs (in 
red, PKH26) in EC and VSMC). The cell nuclei were counter-colored with Hoechst (in blue). 
In the graphs below, FACS analysis related to the internalization of EVs; the cytometric 
detectors allow to highlight the cell population (EC, VSMC) positive for the internalization of 
colored EVs in comparison with the control (cells not stimulated by EVs, identified by the 
green line). 
 
Finally, the degree of osteoblastic differentiation of VSMC incubated with the CKD-
EVs pool from the study cohort was assessed.  
67  
The different intensity of staining was detected by the absorbance; this parameter 
in uremic patients compared with healthy controls was statistically significant 
(p<0,05), with an absorbance average of 0,1  0,005 in CKD patients and 0,055  
0,001 in healthy controls (Figure 43). 
 
Fig. 43: Absorbance degree associated with intensity quantification for Alizarin red staining 
in vitro by VSMC incubated with EVs from uremic sera. In the boxes, examples illustrating 
different degrees of osteoblastic differentiation presented by VSMC 
 
All effects induced by CKD-EVs on the different cell types were enhanced by co-
incubation with uremic toxins PBUT (indoxyl sulfate) and were significantly 
reduced following pre-treatment with RNase, enzyme able to degrade mRNA and 
miRNA. 
  





This study has been oriented mainly in two directions: on the one hand the attempt 
to identify new markers of cardiovascular disease in the uremic patient and on the 
other to understand what mechanisms may correlate chronic kidney damage with 
the increased cardiovascular mortality of these patients. 
 
7.1. Effectiveness of dialytic filters with adsorbent properties reducing 
sCD40L levels, inflammatory processes, and related vascular damage.  
Chronic kidney disease, as a model of early senescence and fragility, is 
characterized by a persistent inflammatory status, which is predominantly 
mediated by some circulating uremic toxins identified in recent years as medium 
and large molecules and as PBUT (Protein Bound Uremic Toxins). These 
molecules seem to be able to modulate vascular damage, directly and indirectly 
and, in combination with the altered regulation of bone metabolism, are cause of 
accelerated atherosclerosis of the uremic patient31. 
 
The CD40/CD40L pathway seems to play a key role in the mechanisms 
associated with the development of atherosclerosis and vascular calcifications in 
hemodialysis patients. CD40 is a lymphocytic co-stimulation molecule also present 
on endothelial, epithelial, and smooth vascular muscle cells, with a pro-
inflammatory role that occurs when the molecule is activated by the respective 
ligand, CD40L, expressed by platelets, smooth vascular muscle cells, endothelial 
and epithelial cells37,56.  
sCD40L is the soluble form of CD40L and is typically released by platelets 
because of their activation. This molecule has a complete biological activity and, 
the ligation with CD40 determines the release of cytokines and the expression of 
adhesion molecules. 
 
The RISCAVID study40 was the first to demonstrate the role of sCD40L as a 
marker of cardiovascular risk, as confirmed by a more recent study of Li et al.57 
and Esposito et al.58 which defined sCD40L as a predictive marker of 
cardiovascular morbidity and mortality in hemodialyzed patients. Desideri et al. 
(RISCAVID study) also found an increase in cardiovascular risk in patients treated 
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with bicarbonate hemodialysis (BHD) compared to those treated with 
hemodiafiltration online (OL-HDF), suggesting a possible relationship between 
type of dialytic method (diffusive versus convective-diffusive mixed) and circulating 
levels of sCD40L. 
In addition, recent evidence from Japanese studies suggests that the adoption of 
filters based on the physical principle of adsorption, such as PMMA, can provide 
better purification of uremic toxins than PS. In one of the latest published papers, 
Abe et al.53, based on a cohort of 136,676 hemodialysis patients, showed that 
PMMA is associated with better outcomes in terms of mortality and general 
morbidity. In this work, therefore, a standard hemodialysis replacement therapy 
such as dialysis bicarbonate was evaluated but using adsorbent dialytic filters. The 
adsorbent membrane in PMMA helps to remove medium-high molecular weight 
molecules with a reduction of inflammatory mediators55. There are different 
subtypes of filters, and the PMMA BKF series is particularly effective in eliminating 
molecules of high medium-weight difficult to remove because they are linked to 
plasma proteins, such as sCD40L or PBUT54. 
 
On this basis, our group has therefore launched some translational research 
studies, with the aim on the one hand to assess the effectiveness of HDF-OL and 
absorptive membranes (PMMA filters and Theranova), and on the other hand to 
evaluate new potential diagnostic and therapeutic damage markers, such as 
lymphocytic co-stimulation molecules and EVs. 
 
In the first part of this study, ROC analysis confirmed the biological role of 
sCD40L, finding a strikingly similar threshold value to RISCAVID study as 
predictor of MACE (RISCAVID median values 7.6 ng/ml vs Our ROC value 7.8 
ng/ml). This slight difference between the two cut-off values could be explained by 
the general characteristics of the two populations. In particular, the percentage of 
hypertensive and diabetic patients is greater in our cohort than RISCAVID 
therefore this figure could explain a higher cut-off in our population. Moreover, this 
predictive effect is the strongest and independent risk factor (OR 4.97) compared 
to the traditional risk factors such as diabetes, arterial hypertension, and age. 
sCD40L level and patient’s age are the only independent factors confirmed at 
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multivariate analysis. Therefore, any dialyzer which is proven to reduce sCD40L 
levels could be expected to have a positive impact on cardiovascular risk, which 
represents the first cause of death in dialysis patients. Furthermore, we analyzed 
the efficacy of PMMA BKF in the removal of sCD40L, as well as the role of 
sCD40L in cardiovascular damage. The results, although on a small sample size, 
showed a significant and rapid reduction of the levels of sCD40L, following the 
start of RRT with PMMA BKF filter and at switch from PS to PMMA BKF; 
consistently, the mass removal of sCD40L was higher by adopting the membrane 
in PMMA BKF.  In addition to the reduction of sCD40L levels, the PMMA BKF filter 
seems to have a higher impact in the reduction of hepcidin, since it supports the 
biological plausibility of a protective effect on the inflammatory anemia, the 
accelerated atherosclerotic process, and the vascular disease of CKD.  
 
Of particular interest are the data concerning the removal of PBUT, uremic toxins 
with medium-high molecular weight (e.g., indoxyl-sulfate). Also in this context, the 
adsorbent filter has proven more efficient, reducing PBUT levels by removing more 
mass than PS.  
 
In vitro studies also demonstrated the pro-atherogenic and inflammatory role of 
sCD40L and, for the first time, the existence of a correlation between platelet 
activation status and PBUT levels (resulting in an increase in sCD40L 
concentration). In fact, in the serums of patients treated with the adsorbent 
membrane were detected: 1) a reduced amount of ROS (Reactive Oxygen 
Species) produced by endothelial cells, 2) a reduced adhesion of monocytes at 
endothelial cell level (expression of reduced endothelial activation) and 3) a 
reduced osteoblastic differentiation by smooth vascular muscle cells, all essential 
aspects of the ongoing vasculopathy of uremia. Being the peculiarity of this filter to 
eliminate more effectively sCD40L through adsorption, it is biologically plausible to 
correlate the lower concentration of sCD40L with the anti-inflammatory and 
vascular-protective effects previously mentioned (lower production of ROS, lower 
degree of osteoblastic differentiation and monocyte adhesion). 
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Therefore, the reduction of endothelial dysfunction and calcification of smooth 
muscle cells is probably at least partly due to the reduction of the levels of 
sCD40L, which is achieved not only through direct adsorption of PMMA, but also 
thanks to the adsorption of PBUT stimulating the release of the mediator. It could 
therefore be assumed a double protective effect determined by the membrane in 
PMMA, consisting of a direct effect linked to the adsorbent properties of the same 
and an indirect effect, linked to the removal of PBUT and the resulting reduction in 
platelet release of sCD40L. 
This second "indirect" protective mechanism of PMMA filters has never been 
reported to our knowledge and is therefore a peculiarity of our study. 
 
7.2. Role of extracellular vesicles (EVs) in endothelial dysfunction and 
vascular calcifications in the uremia. 
EVs are newly discovered structures released by multiple cell types and implicated 
in intercellular communication59. EVs appear to be increased in CKD patients, with 
a predominantly endothelial and platelet origin; in addition, their levels would 
correlate directly with an increased cardiovascular risk46,49(p142). In the second part 
of this study, we first confirmed that the EV concentration was increased in CKD 
patients compared to healthy controls. In addition, the analysis of the expression 
of different membrane antigens allowed to highlight the increase of endothelial 
EVs in uremic patients compared to controls. The finding of a positivity for markers 
related to inflammation, endothelial dysfunction, and vascular calcification, allowed 
to hypothesize that the EVs are involved in these phenomena. In particular, 
CD40L and ICOS lymphocytic co-stimulation molecules positivity on EV surface 
makes the hypothesis of an involvement of EVs in the development of pro-
atherogenic and pro-inflammatory phenomena more plausible. 
 
The progression of cardiovascular damage as a result of the action of EVs 
appears confirmed in some studies described in the Literature, such as those 
carried out by Stenvinkel et al., which described the alterations induced by the EVs 
in uremia on muscle relaxation mediated by nitric oxide (NO), exploiting "ex vivo" 
models of isolated vessel11,32. In addition, Lee et al.60 described the release of EVs 
from patients with IMA and the subsequent inoculation in experimental rats 
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favoring vasomotor dysfunction and formation of local clots.  In addition, EVs of 
monocytic and lymphocytic origin have been identified in atherosclerotic plaques, 
with higher concentration than those of platelet origin. Boulanger et al.45 have 
shown that EVs are present in atherosclerotic plaque and derived from leucocyte 
and smooth muscle cells. Finally, EVs isolated from atherosclerotic plaques can 
transfer molecules such as ICAM-1 to endothelial cells, thus facilitating the 
adhesion and transmigration of leukocytes in such locations. 
 
In our study, the pathological effects of EVs appear to be mediated not only by the 
action of membrane proteins, but also by the presence of miRNA carried by EVs 
(e.g., the most important seems to be miR-223). This genetic material seems to 
act on endothelial cells and smooth vascular muscles, following the internalization 
of EVs, as observed in FACS and microscopic analyses performed in vitro. A pro-
calcific role associated with the internalization of the EVs was noted, presumably 
associated with miR-223 action. These results confirm the data present in 
Literature61 and therefore suggest that the EVs not only play a role of biomarkers, 
but also are effective damage mediators, as real uremic toxins. According to this 
interpretation, all previous effects induced by EVs on different cell types were 
enhanced by co-incubation with uremic PBUT toxins (p-cresyl sulfate or indoxyl 
sulfate) and significantly reduced by pre-incubation RNase treatment, an enzyme 
that can destroy miRNA. 
 
Useful insights for the correlation of these laboratory data with clinical data of 
cardiovascular damage could be represented by: 1) detection of aPWV (Pulse 
Wave Velocity), an indirect measure of aortic wall stiffness, and 2) detection of the 
thickness of the intimate of the carotid artery (cIMT), a systemic atherosclerotic 
disease index62. Moreover, a study of patients with CKD in stage IV-V analyzed 
the relationship between circulating endothelial EVs and endothelial dysfunction, 
showing that the concentration of CD144+ EVs (caderine of vascular endothelium) 
was correlated with the vessel’s capacity to dilate in response to increased blood 




7.3. Strengths and limitations of the study 
This study has some strengths and some limitations. Among the strengths, the 
main is the analysis and characterization of the EVs, which represent a new 
frontier, and which will likely provide much information on the mechanisms of the 
disease and many potential biomarkers, not only within the CKD, but also for other 
diseases. In fact, the EVs are involved in different pathological processes and 
could also be exploited, as well as biomarkers, also as a new therapeutic tool of 
negative modulation of different pathological processes (see "Future 
Perspectives"). 
 
An important strength lies in the fact that the study is part of a project dedicated to 
the identification of the most effective dialysis methods for treatment, and to the 
prevention of the development of cardiovascular damage in patients with CKD, 
main factor of mortality and morbidity in this cohort. As previously noted, the 
identification of "non-traditional" risk factors, associated with the high increase in 
cardiovascular risk associated with CKD patients, has been the subject of study for 
many years because of the relevant clinical implications. The results of our study 
provide new evidence in this area, configuring the EVs and the co-stimulation 
molecule sCD40L as possible new actors in the pathogenesis of vascular damage 
in the uremia, and suggesting that certain RRT may be effective in inhibiting these 
processes.  Among the limitations of the study, the reduced size of the enlisted 




Our study provides new insights into the cardiovascular protective effect of PMMA, 
as compared with PS, supporting the hypothesis that this dialyzer is more efficient 
in removal of sCD40L due to its adsorptive properties. Not only PMMA BKF is 
associated with a lower degree of inflammation, but also with an improvement of 
endothelial dysfunction and vascular calcification processes, mediated by the 
reduction of sCD40L and hepcidin levels. In fact, the in vitro study of sera treated 
with PMMA BKF, characterized by reduced levels of sCD40L, showed 1) a 
reduced stimulus to the production of ROS (Reactive Oxygen Species) by 
endothelium, 2) a reduction of endothelial activation (expressed by reduced 
monocytic adhesion) and finally 3) the degree of osteoblastic differentiation of 
smooth vascular muscle cells. The results highlight the impact of the removal of 
this soluble molecule on several aspects related to chronic micro-inflammation of 
the uremia. At the same time, we assessed the PMMA BKF ability to adsorb 
PBUTs - such as indoxyl sulfate (IS) - which are able to determine the exposure of 
CD40L on the platelet membrane and the consequent cleavage, with release of 
sCD40L. This represents an unprecedented mechanism of modulation of CD40L 
levels because the PMMA dialyzer, can effectively break down both sCD40L and 
PBUT levels, inhibiting the platelet release of sCD40L. 
Moreover, we found that EVs concentration is significantly increased in CKD 
patients with a predominantly platelet and endothelial origin. The expression of the 
CD40L and other molecules potentially implicated in inflammatory, pro-apoptotic 
and pro-coagulant processes (ICOS, C5b-9, TF, FAS-L) has been demonstrated 
on the surface of the EVs suggesting that these can contribute to the development 
of functional alterations of endothelial and smooth muscle cells in the uremic 
patients. Furthermore, the EV effects are also attributable to the transfer of gene 
material including some specific miRNA. To confirm this hypothesis, we observed 
in vitro that the biological activity of EVs significantly modulated the degree of 
osteoblastic differentiation of smooth muscle cells. In particular, in CKD patients 
mir-223 expression was higher than healthy controls and CKD EVs therefore 
appear to act synergically with the uremic toxins in the development of endothelial 
and smooth muscle cell damage, through the action of membrane proteins and 
horizontal transfer of miRNA. In addition, all EVs effects were enhanced by co-
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incubation with uremic PBUT toxins and were significantly reduced following pre-
treatment with RNase. 
In conclusion, sCD40L does not appear exclusively a marker of cardiovascular 
damage in the uremic patient, but also a mediator of the CV progression. The 
reduction of sCD40L levels using adsorbent filters (PMMA BKF) could therefore 
have an impact on the reduction of cardiovascular risk in the CKD patient. In 
addition, our work allows us to outline a role of potential biomarker for the 
development risk of MACE, providing new evidence about the mechanisms of 
damage. Similarly, EVs are biomarkers and main players of cardiovascular 
damage in uremia. The EVs internalization and the transfer of specific miRNA, 
could play a key role towards inflammation, endothelial dysfunction, vascular 
calcification, and development of cardiovascular disease in the uremic patient. The 
EVs would therefore constitute real uremic toxins. Further studies should be 
carried out to understand through which mechanisms the genetic material 
contained within EVs, and the proteins expressed on their surface interact with the 
surrounding environment modulating molecular pathways that can contribute to 
damage progression. 
 
8.1. Milestones and deliverables 
The results of this study will be presented at national and international scientific 
meetings and are currently submitted to a peer-reviewed scientific journal. 
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9. Future perspective 
One of the main perspectives is the begin of a prospective study on a larger 
population, with a duration of at least 5 years, in order to verify the correlation 
between the use of different dialytic filters (PMMA/BHD), serum levels of sCD40L 
and MACE. The correlation between sCD40L and cardiovascular events would in 
fact represent an important relapse of our work from the clinical point of view and 
would confirm the initial evidence of the Literature on this topic. If the role of 
sCD40L will be confirmed, the determination of its levels could be used to stratify 
the cardiovascular risk of CKD patients, thus assuming a new role as biomarker 
and therapeutic target. 
Another possible development could be a further study to evaluate the role of 
CD40L through genetic silencing of CD40L (for example through siRNA - small 
interfering RNA) in the endothelial cell and smooth muscle cell, to verify the 
abrogation of the effects associated with sCD40L in our study. 
Of interest, the interactions between CD40/CD40L and other co-stimulation 
molecules, such as the ICOS/ICOSL system, could represent an additional field of 
study, considering that these molecules were expressed on the surface of EVs in 
our results. Moreover, there are numerous data in the Literature supporting a role 
in the regulation and modulation of cardiovascular damage by the ICOS/ICOSL 
pathway, in particular in relation to atherosclerosis37,38. 
In addition to T-cell co-stimulatory pathways, the role of EVs in uremia should be 
considered in depth. The results of our study suggest that the EVs do not have a 
simple role of biomarkers but can be active mediators in the development of 
vascular damage typical of uremia. Their function as "carriers" of pro-atherogenic 
and anti-angiogenic genetic material makes them ideal candidates to study the 
mechanisms of damage of uremia and therefore, in perspective, to identify miRNA 
that can be used both as biomarkers (for example, mirna-223) and as therapeutic 
targets. The development of monoclonal antibodies able to inhibit the 
internalization of EVs, or interfering RNA or specific miRNA with inhibitory activity 
against pathogenic miRNA, are possible developments with modern 
biotechnology. Furthermore, it could be hypothesized a removal of EVs through 
the use of absorptive membrane (e.g. PMMA BKF). 
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Finally, the elimination of both PBUT and sCD40L by dialyzers with PMMA BKF 
will be of great interest in the future. According to the Literature, the treatment of 
high volume convective hemodialytic infusion (HDF) would determine the best 
clinical outcomes, being associated with a more effective removal of medium-large 
toxic molecules. It could therefore be assumed that the combined use of 
absorptive membranes (e.g. PMMA, Theranova) and HDF-OL could be the most 
effective elimination modality of traditional and "non-traditional" uremic toxins with 
an optimization of the positive effects on the slowing of the progression of 
cardiovascular damage.  
 
9.1. Other research projects related to the main study 
Based on the results obtained in the main study and literature data, we carried out 
- during the three-years of PhD program - 2 other research project to investigate 
the potential efficacy of other hemodialytic strategies: 
• Theranova study: a multicenter, prospective, one-arm, clinical study, lasting 6 
months. In this study were enrolled 60 patients with CKD stage V according to 
K/DOQI in chronic bicarbonate hemodialytic treatment and at the beginning of 
the study they switched to a hemodialytic treatment with a new absorption 
membrane, called Theranova, for 6 months. At the beginning of the study (T0) 
and therefore every month all patients underwent to blood sampling for 
evaluation of inflammation markers and uremic toxins. The results of this study 
showed the ability of the Theranova membrane to reduce blood concentrations 
of certain uremic toxins (medium molecules) such as  2-microglobulin (Table 
19 and Figure 44), free light chains (Tables 20-21 and Figure 45-46) and 










Tab. 19 2-microglobulin concentrations (median and IQR) at different time points. 
Statistically significant differences were found in the variance analysis with Friedman Test 
(p < 0.0001) and Wilcoxon Signed Ranks Test 
 
 
Fig. 44: Box plot (median and IQR) for 2-microglobulin concentrations at different time 
points within two groups.  
 
Tab. 20 Light chain Lambda concentrations (median and IQR) at different time points. 
Statistically significant differences were found in the variance analysis with Friedman Test 
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Fig. 45: Box plot (median and IQR) for light chain Lambda concentrations at different time 
points within two groups.  
 
Tab. 21 Light chain Kappa concentrations (median and IQR) at different time points. 
Statistically significant differences were found in the variance analysis with Friedman Test 
(p < 0.0001) and Wilcoxon Signed Ranks Test 
 
 
Fig. 46: Box plot (median and IQR) for light chain Kappa concentrations at different time 
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Tab. 22 Myoglobin concentrations (median and IQR) at different time points. Statistically 
significant differences were found in the variance analysis with Friedman Test (p = 0.031) 
and Wilcoxon Signed Ranks Test 
 
 
Fig. 47: Box plot (median and IQR) for myoglobin concentrations at different time points 
within two groups.  
 
This study confirms the dialytic efficacy of Theranova membrane in eliminating 
molecules of medium weight compared to PS. The results of this study are 
currently submitted to a peer-reviewed scientific journal 
• CRC-CARIPLO study: a multicenter, prospective, three-period, 
randomized, crossover clinical study, lasting 18 months. In this study were 
enrolled 47 patients with CKD stage V according to K/DOQI in chronic 
hemodialytic treatment. The inclusion criteria were: 1) Age between 18 and 80 
years, 2) Hemodialysis treatment with BHD for at least 1 month, three-weekly 
rhythm, 12 hours/week; 3) diuresis <500 ml/ day; 4) Qb > 250 ml/min and 5) 
mean Kt/V >1.2. We excluded patients with local or systemic acute infectious 
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T3-T0 p = 0,375 
T6-T0 p = 0,121 
T6-T3 p = 0,015* 
81  
melanoma), patients with kidney transplantation in place but no longer 
functioning, patients with autoimmune diseases or active vasculitis. The 
patients were randomized in three arms to continue BHD or switch to mOL-
HDF or absorption membrane (PMMA or Theranova) and every 6-months they 
will switch to a different dialytic treatment. At the beginning of the study (T0) 
and therefore every 3 months all patients underwent to blood sampling for 
quantification and characterization of plasma MVs and miRNA content and 
evaluation of inflammation markers and uremic toxins (Figure 48). Moreover, at 
the time of modification of the dialysis therapy every 6 months all patients 
evaluated arterial stiffness by PWV, thickness of the carotid wall using 
ecoDoppler and diastolic dysfunction by echocardiogram. We also performed 
in vitro studies on EC and VSMC to evaluate the pathogenic role of EV isolated 
from CKD plasma and Ex vivo studies on isolated human arteries to assess the 
effect of uremic EV on the mechanics of contraction and relaxation of the 
vessel. The ex vivo experiments will be performed in collaboration with Prof. 
Peter Stenvinkel, Karolinska Institutet (Stockholm, Sweden).  
 
Fig. 48: CRC-Cariplo study protocol 
 
Up to now, the study is over, and we are concluding the experiments and 
the statistical analysis. We performed in vitro study using plasma EVs 
isolated from healthy subject, BHD and mOL-HDF patients at T0 and T6. 
EVs isolated from plasma of T0 HD patients measured around 162 nm and 
were meanly concentrated at 2x1011 particles/ml (Figure 49). 
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Fig. 49: Average concentration (particle/ml) and size (nm) of EVs from T0 samples 
 
Concerning the surface protein expression, the most expressed markers are 
typical of T cells, in particular activated T cells and the cytotoxic subpopulation, 
B cells, macrophages, antigen presenting cells, platelets, and endothelial cells. 
Interestingly, there are difference between T0 and T6 samples. Results 
suggested that in T6 samples compared to T0 samples, there was a decrease 
of EVs deriving from general T cell population (Figure 50), immature B cell 
population, macrophages, platelets (Figure 51), antigen, presenting cells 
(Figure 52), exosomes. The decrease in markers expression may mean a 
reduction of the EVs themselves after the hemodialysis.  
 
Fig. 50: Percentage of expression of T cell surface markers. In A, CD3 marked PE; in B, 
CD8 marked FITC; in C, CD4 marked PE; in D, CD178 marked PE. The data are expressed 
as percentage of positive cells, relative to the isotype control. Reported data are means 
± SD of five independent experiments. Short square brackets indicate significance 




1. EVs SIZE AND CONCENTRATION 
 
Size and concentration of EVs were measured with the NanoSight instrument.  
As shown in the Figure 1., the average size of EVs in T0 samples is about 162 nm. 
The mean of EVs concentration in T0 samples is around 2x1011 particles/ml (Figure 
2.). 
 
Figure 1. Average concentration (particle/ml) of EVs from T0 samples.  
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2. EVs SURFACE MARKER ANALYSIS 
 
Coming with the derivation of EVs, many surface markers from different cell types 
were analyzed through flow cytometry.  
Results shown in Figure 3. demonstrate the T cell and activated T cell derivation: CD3 
is expressed in the 26% of EVs from T0 samples and in the 17% of EVs from the T6 
samples, with a significant difference between T0 and T6; CD4 is expressed in the 
16% of EVs fr  T0 samples and in the 25% of EVs from th  T6 samples, with a 
significant difference between T0 and T6. As regarding CD8 and CD178 no 
statistically significant difference can be observed between T0 and T6 samples. 
 
Figure 3. Percentage of expression of T cell surface markers. In A, CD3 marked PE; in B, CD8 marked 
FITC; in C, CD4 marked PE; in D, CD178 marked PE. The data are expressed as percentage of positive 
cells, relative to the isotype control. Reported data are means ± SD of five independent experiments. 
Short square brackets indicate significance between groups (P<0.05). 
 
Results shown in Figure 4. demonstrate the B cell derivation: CD19 is expressed in the 






Fig. 51: Percentage of expression of platelet surface markers. In A, CD41a marked FITC; 
in B, CD41b marked FITC; in C, CD42b marked FITC. The data are expressed as 
percentage of positive cells, relative to the isotype control. Reported data are means ± 
SD of five independent experiments. Short square brackets indicate significance 
between groups (P<0.05). 
 
 
Fig. 52: Percentage of expression of antigen presenting cell surface markers. CD40 
marked FITC. The data are expressed as percentage of positive cells, relative to the 
isotype control. Reported data are means ± SD of five independent experiments. Short 
square brackets indicate significance between groups (P<0.05). 
 
Different results were obtained as regarding EVs deriving from ECs. Hence, we 
observed a fall of the percentage in T6 samples of EVs marked with CD81, 




Figure 6. Percentage of expression of leukocyte surface markers. CD11b marked PE. The data are 
expressed as percentage of positive cells, relative to the isotype control. Reported data are means ± SD 
of five independent experiments. Short square brackets indicate significance between groups (P<0.05). 
 
Results shown in Figure 7. demonstrate the platelet derivation: CD41a is expressed in 
the 0,8% of EVs from T0 samples and in the 3% of EVs from the T6 samples, with a 
significant difference between T0 and T6; CD41b is expressed in the 1,5% of EVs 
from T0 samples and in the 7% of EVs from the T6 samples, with a significant 
difference between T0 and T6; CD42b is expressed in the 33% of EVs from T0 
samples and in the 23% of EVs from the T6 samples, with a significant difference 






Figure 7. Percentage of expression of platelet surface markers. In A, CD41a marked FITC; in B, CD41b 
marked FITC; in C, CD42b marked FITC. The data are expressed as percentage of positive cells, relative 
to the isotype control. Reported data are means ± SD of five independent experiments. Short square 
brackets indicate significance between groups (P<0.05). 
 
Results shown in Figure 8. demonstrate the antigen presenting cell derivation: CD40 
is expressed in the 27% of EVs from T0 samples and in the 18% of EVs from the T6 
samples, with a significant difference between T0 and T6. 
 
Figure 8. Per ntage of expression of a tigen presenting c ll surface markers. CD40 marked FITC. The 
data are expressed as percentag  of positive cells, relative to the is type control. Reported data ar  
means ± SD f fiv  indepen ent experiments. Short square brack ts in icate significance between 
groups (P<0.05). 
 
Results shown in Figure 9. emonstrate the endothel al cell and the activated 
endothelial cel  derivation: CD146 is expressed in the 2% of EVs from T0 samples and 
in t e 4% of EVs from the T6 samples, with a significant differ nce betw en T0 and 
T6; CD62e is expressed in the 39% of EVs from T0 samples and in the 51% of EVs 





Instead, we found an increase of markers for activated ECs, such as CD62e 
and CD146 from T0 to T6 samples (Figure 53).  
 
Fig. 53: Percentage of expression of endothelial cell surface markers. In A, CD146 
marked PE; in B, CD62e marked PE. The data are expressed as percentage of positive 
cells, relative to the isotype control. Reported data are means ± SD of five independent 
experiments. Short square brackets indicate significance between groups (P<0.05). 
 
Results on endothelial cell markers might suggest that, even if the dialysis 
membrane is more efficient in capturing the EVs, the mechanical stress of the 
process itself may cause endothelial stress, leading to its activation and EVs 
release. The same concept might be further attributed to EVs characterized 
with the marker (CD11b) that is involved in many adhesion-related associations 
between leukocytes, which was found to be increased from T0 to T6 samples. 
Also, some markers related to mature B cells, helper T cells, and platelets 
increased their expression on EVs during time. In the case of the rise in mature 
B cells and helper T cells derivation, a possible explanation can be addressed 
to the inflammatory reaction triggered by the dialysate content or the dialysis 
membrane, which stimulates helper T cells to activate mature B cells in order 
to produce antibodies against not-self molecules. Concerning the time- course 
elevation in time of EVs deriving from platelets (CD41a and CD41b markers), 
that finding was in contrast with finding about another platelets surface marker 
(CD42b), which decreased in T6 samples. In this case, it is also important to 
check the percentage of expression of these markers, in fact the CD42b 
marker is much more expressed in both T0 and T6 samples compared to 
CD41a and CD41b markers. Thus, it would be more reliable to take in account 
the trend of the CD42b marker when talking about EVs deriving from platelets, 
stating that they decrease from T0 to T6 samples. Furthermore, EVs deriving 
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Figure 7. Percentage of expression of platelet surface markers. In A, CD41a marked FITC; in B, CD41b 
marked FITC; in C, CD42b marked FITC. The data are expressed as percentage of positive cells, relative 
to the isotype control. Reported data are means ± SD of five independent experiments. Short square 
brackets indicate significance between groups (P<0.05). 
 
Results shown in Figure 8. demonstrate the antigen presenting cell derivation: CD40 
is expressed in the 27% of EVs from T0 samples and in the 18% of EVs from the T6 
samples, with a significant difference between T0 and T6. 
 
Figure 8. Percentage of expression of antigen presenting cell surface markers. CD40 marked FITC. The 
data are expressed as percentage of positive cells, relative to the isotype control. Reported data are 
means ± SD of five independent experiments. Short square brackets indicate significance between 
groups (P<0.05). 
 
Results shown in Figure 9. demonstrate the endothelial cell and the activated 
endothelial cell derivation: CD146 is expressed in the 2% of EVs from T0 samples and 
in the 4% of EVs from the T6 samples, with a significant difference between T0 and 
T6; CD62e is expressed in the 39% of EVs from T0 samples and in the 51% of EVs 





from cytotoxic T cells and activated T cells did not change in percentage from 
T0 to T6 samples, which could be due to the release of pro- inflammatory 
mediators and cell-mediated cytotoxicity caused by the dialysis procedure. 
Moving to the in vitro experiments, results show that after the stimulation with 
EVs, endothelial cells are notably less viable, as confirmed through the 
mitochondrial membrane potential test, and produce more oxidants in form of 
ROS and NO (Figure 54).  
 
Fig. 54: Time-course effects of EVs from T0 samples on (A) cell viability, (B)  
mitochondrial membrane potential, (C) NO release and (D) ROS release in ECs. The data 
are normalized versus control value. Reported data are means ± SD of five independent 
experiments. Significance between groups: *P<0.05 vs C. Short square brackets indicate 
significance between groups (P<0.05). 
 
All of these results are time dependent that means that the more EVs are on 
ECs, the highest is cell damage that they cause. Therefore, taken altogether, 
these results demonstrate the role of the EVs on triggering the renal 
endothelial cells damage. On the other hand, in vitro experiments on VSMCs 
suggest that in the presence of EVs, they activate themselves as demonstrated 
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3. IN VITRO EXPERIMENTS – ENDOTHELIAL CELLS 
 
3.1 MTT CELL GROWTH ASSAY  
 
In order to study the vit lity of ECs stimulat  with EVs from T0 sample , MTT assay 
was carried out at different timing stimulation. 
As illustrated in Figure 12., time-course studies show a significant gradual decrease in 
cell viability with stimulating time from 12 h to 48 h. Therefore, a time-dependent 
response is observed in ECs stimulated with EVs. 
 
Figure 12. Time-course effects of EVs from T0 samples on cell viability in ECs. The data are normalized 
versus control value. Reported data are means ± SD of five independent experiments. Significance 
between groups: *P<0.05 vs C. Short square brackets indicate significance between groups (P<0.05). 
 
3.2 MITOCHONDRIAL MEMBRANE POTENTIAL 
EVALUATION 
 
To confirm the cell viability trend, the time-course effect of EVs from T0 samples on 
the mitochondrial membrane potential of ECs was tested using the JC-1 reagent.  
The mitochondrial membrane potential is significantly decreased following a time-




Figure 13. Time-course effects of EVs from T0 samples on mitochondrial membrane potential in ECs. 
The data are normalized versus control value. Reported data are means ± SD of five independent 
experime ts. Significance between groups: *P<0.05 vs C. Short square brackets indicate significance 
between groups (P<0.05). 
 
3.3 NITRIC OXIDE RELEASE ASSAY 
 
The toxic effect of EVs on ECs was analyzed in time, by measuring the NO production 
through the Griess assay. 
As shown in Figure 14., the stimulation of ECs with EVs from T0 samples causes a 
significant and general time-dependent increase of NO release. 
 
Figure 14. Time-course effects of EVs from T0 samples on NO release in ECs. The data are normalized 
versus control value. Reported data are means ± SD of five independent experiments. Significance 
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3.4 ROS PRODUCTION MEASUREMENT 
 
Finally, also the ROS production by ECs stimulated at different timing with EVs was 
measured. 
Figure 15. evidences significant time-dependent trend, in that the longer ECs are 
stimulated the more they release ROS (Figure 15.). 
 
Figure 15. Time-course effects of EVs from T0 samples on ROS release in ECs. Reported data are 
means ± SD of five ind pende t experiments. Significance between groups: *P<0.05 vs C. Short square 





by the increase in cell viability and mitochondrial membrane potential, and the 
increased [Ca2+] in cytoplasm. In fact, it is possible to hypothesize that EVs 
may influence the movement of calcium from the extracellular environment, 
since in the presence of EGTA (calcium-chelanting agent) EVs did not have 
any effect in the increase of [Ca2+]c. Moreover, EVs in the presence of ATP, 
were able to reduce the effects of ATP alone on [Ca2+]c. Taken altogether, 
results on VSMCs indicate that when they are stimulated with EVs from T0 
samples, they turn into activated cells, increase their calcium content which 
could be used for their contraction (Figure 55). 
 
Fig. 55: Time-course effects of EVs from T0 samples on (A) cell viability and (B) 
mitochondrial membrane potential in VSMCs. The data are normalized versus control 
value. Reported data are means ± SD of five independent experiments. Short square 
brackets indicate significance between groups (P<0.05). (C) Analysis of intracellular 
Ca2+ pool mobilized by EVs of T0 samples in VSMCs. EGTA (50 mM), ATP (10 μM). The 
results are the mean ± SD of 5 experiments for each experimental protocol 
 
It is notable that this event is at the basis of vasoconstriction and hypertension, 
which is a typical feature of end-stage CKD patients. Further, an increase of 
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4. IN VITRO EXPERIMENTS – SMOOTH MUSCULAR 
CELLS 
 
4.1 MTT GROWTH ASSAY 
 
The MTT assay was performed also on VSMCs to check their vitality once stimulated 
at different timing with EVs. 
As illustrated in Figure 16., time-course studies show a gradual increase in cell 
viability from 12 h to 48 h stimulation with EVs of T0 samples. Therefore, a time-
dependent response can be observed in VSMCs stimulated with EVs. 
 
Figure 16. Time-course effects of EVs from T0 samples on cell viability in VSMCs. The data are 
normalized versus control value. Reported data are means ± SD of five independent experiments. Short 
square brackets indicate significance between groups (P<0.05). 
 
4.2 MITOCHONDRIAL MEMBRANE POTENTIAL 
 
As a confirm of the cell viability trend, the mitochondrial membrane potential 
evaluation was carried out. 
Figure 17. shows an increase in the mitochondrial membrane potential following a 
time-dependent response when VSMCs are stimulated with EVs of T0 samples from 




Figure 17. Time-course effects of EVs from T0 samples on mitochondrial membrane potential in 
VSMCs. The data are normalized versus control value. Reported data are means ± SD of five 
independent experiments. Significance between groups: *P<0.05 vs C. Short square brackets indicate 
significance between groups (P<0.05). 
 
4.3 CYTOSOLIC CALCIUM ([Ca2+]C) MOVEMENT 
 
Cytosolic calcium movement was analyzed during time, in VSMCs stimulated with 
EVs, EGTA, EGTA+EVs, ATP, ATP+EVs, using the FURA 2-AM reagent. 
Figure 20. shows that EVs of T0 samples, in about 1 min are able to stimulate VSMCs 
to increase the [Ca2+]c to about 104 nM, from the basal concentration of around 97 
nM. When a calcium-chelating molecule as EGTA is added to the cells, [Ca2+]c 
decreases below its basal concentartion, and the addition of EVs in this condition does 
not contribute to [Ca2+]c increase. Moreover, ATP alone added to cells stimulates 
them to raise up the [Ca2+]c to about 115 nM, but when ATP and EVs are both added 





Figure 20. Analysis of intracellular Ca2+ po l mobilized by EVs of T0 samples in VSMCs. EGTA (50 
mM), ATP (10 µM). The results are the mean ± SD of 5 experiments for each experimental protocol. 
  




cytosolic calcium could be followed by the activation of oxidative stress 
mechanisms at the basis of apoptosis. 
The expected results of this project could lead to the identification of new 
therapeutic targets with a translational approach that put together in vitro 
studies on endothelial and smooth muscle cells, ex vivo studies on isolated 
human arteries and clinical evaluation of cardiovascular damage through 
analysis of arterial stiffness, carotid thickness and diastolic dysfunction. 
Furthermore, the identification of the pathogenic role of plasma EV may lead to 
the identification of new pathways, thus allowing to block the progression 
toward ESRD as well as the cardiovascular damage. As a future approach, the 
identification of EV surface molecules essential for their internalization into 
target cells, could also lead to the development of therapeutic monoclonal 
antibodies able to inhibit this internalization. Evaluation of mRNA and 
particularly microRNA involved in these mechanisms of damage will be more 
interesting for the potential development of therapeutic strategies based on the 
administration of small interfering RNA (siRNA) or specific inhibitors of 
microRNAs (antagomiRs). Finally, the identification of the pathogenic role of 
circulating plasma EV in the inflammatory environment could also find 
application in disease other than CKD and CVD and characterized by patients’ 
frailty such as sepsis and cancer, diseases more prevalent in the older 
population. The development of extracorporeal therapies and specific inhibition 
of mRNA and microRNA present in circulating EV as assumed in this research 
project could be applied, therefore, also in these pathologies with additional 
beneficial impact on the regional and national health care systems. 
 
10. Other research activities during PhD program 
During the PhD program, further studies were carried out in other fields of 
research such as kidney transplantation starting national collaborations, as follow: 
• We collaborated with Virology and Urology Units of our University to evaluate 
the role of BK polyomavirus (BKPyV) reactivation in the development of kidney 
and urothelial cancer in kidney transplant recipients (KTRs). In a retrospective 
single center cohort of KTRs (n = 1307), 10 clear cell renal cell carcinomas and 5 
urinary bladder carcinomas were analyzed from 15 KTRs for the presence of 
88  
BKPyV infection through immunohistochemistry and fluorescent in situ 
hybridization (FISH). Three of these patients had already exhibited biopsy-proven 
polyomavirus-associated nephropathies (PyVAN). Although the presence of 
BKPyV large-T antigen was evident in the urothelium from a kidney removed soon 
after PyVAN diagnosis, it was undetectable in all the formalin-fixed and paraffin-
embedded (FFPE) blocks obtained from the 10 kidney tumors. By contrast, large-T 
antigen (LT) labeling of tumor cells was detected in two out of five bladder 
carcinomas. Lastly, the proportion of BKPyV DNA-FISH-positive bladder 
carcinoma nuclei was much lower than that of LT-positive cells. Taken together, 
our findings further strengthen the association between BKPyV reactivation and 
cancer development in KTRs, especially bladder carcinoma. The results of this 
study were published in a peer-reviewed journal (Borgogna C, Albertini S, 
Martuscelli L, Poletti F, Volpe A, Merlotti G, Cantaluppi V, Boldorini R, Gariglio M. 
“Evidence of BK Polyomavirus Infection in Urothelial but not Renal Tumors from a 
Single Center Cohort of Kidney Transplant Recipients”. Viruses. 2021; 13(1):56. 
doi:10.3390/v13010056) 
• We collaborated with Nephrology and Transplant Unit of University of Bari to 
assess the role of the extracellular vesicles in endothelial-to-mesenchymal 
transition and tubular senescence in renal antibody-mediated rejection. This 
collaboration leaded to 4 accepted abstracts in international congresses and 
publicized in peer-reviewed journal (Franzin R, Divella C, Stasi A, Sallustio F, 
Curci C, Merlotti G, Quaglia M, Cantaluppi V, Gesualdo L, Castellano G 
"Extracellular Vesicles can mediate tubular inflammaging in Antibody-Mediated 
Rejection via Cyclin-Dependent Kinase Inhibitors", Nephrology Dialysis 
Transplantation, June 2019 - Vol. 34, (Issue suppl 1); - Cantaluppi V, Merlotti G, 
Quaglia M, Rosso G, Clemente N, Cappellano G, Chiocchetti A, Castellano G, 
Dianzani U, Camussi G. “Activation of the ICOS/ICOS-Ligand Pathway in 
Antibody-Mediated Kidney Graft Rejection” [abstract]. Am J Transplant. 2020; 20 
(suppl 3); - Castellano G, Franzin R, Stasi A, Divella C, Merlotti G, Quaglia M, 
Sallustio F, Stallone G, Cantaluppi V, Gesualdo L. “Extracellular Vesicles Mediate 
Endothelial to Mesenchymal Transition and Tubular Senescence in Renal 
Antibody- Mediated Rejection by Inducing Complement Activation” [abstract]. Am J 
Transplant. 2020; 20 (suppl 3).; - Franzin R, Stasi A, Sallustio F, Divella C, 
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Merlotti G, Quaglia M, Curci C, Stallone G, Cantaluppi V, Gesualdo L, Castellano 
G, "Plasma extracellular vesicles mediate endothelial to mesenchymal transition 
and tubular senescence in renal antibody mediated rejection by complement 
activation” Nephrology Dialysis Transplantation, June 2020 - Vol. 35. (Issue suppl 
3), gfaa141.doi:10.1093/ndt/gfaa141.TO007) 
 
In addition, these two collaborations have allowed the realization of 3 reviews 
published in peer-reviewed journals on the following topics: 
o New biomarkers of kidney graft dysfunction: (1) Quaglia M, Merlotti G, 
Guglielmetti G, Castellano G, Cantaluppi V. “Recent Advances on Biomarkers of 
Early and Late Kidney Graft Dysfunction”. Int. J. Mol. Sci. 2020, 21, 5404. 
doi:10.3390/ijms21155404; (2) Quaglia M, Dellepiane S, Guglielmetti G, Merlotti 
G, Castellano G, Cantaluppi V. “Extracellular Vesicles as Mediators of Cellular 
Crosstalk Between Immune System and Kidney Graft”. Front Immunol. 
2020;11:74. doi:10.3389/fimmu.2020.00074 
o Systemic Lupus Erythematosus and viral infection (Quaglia M, Merlotti G, De 
Andrea M, Borgogna C, Cantaluppi V, “Viral Infections and Systemic Lupus 
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